2,129 results on '"Lymphoma, B-Cell therapy"'
Search Results
152. Investigation of product-derived lymphoma following infusion of piggyBac-modified CD19 chimeric antigen receptor T cells.
- Author
-
Micklethwaite KP, Gowrishankar K, Gloss BS, Li Z, Street JA, Moezzi L, Mach MA, Sutrave G, Clancy LE, Bishop DC, Louie RHY, Cai C, Foox J, MacKay M, Sedlazeck FJ, Blombery P, Mason CE, Luciani F, Gottlieb DJ, and Blyth E
- Subjects
- Aged, DNA Transposable Elements, Gene Expression Regulation, Neoplastic, Gene Transfer Techniques, Humans, Immunotherapy, Adoptive methods, Leukemia, B-Cell genetics, Leukemia, B-Cell therapy, Lymphoma genetics, Lymphoma, B-Cell genetics, Lymphoma, B-Cell therapy, Male, Receptors, Antigen, T-Cell genetics, T-Lymphocytes metabolism, Transcriptome, Transgenes, Immunotherapy, Adoptive adverse effects, Lymphoma etiology, Receptors, Antigen, T-Cell therapeutic use
- Abstract
We performed a phase 1 clinical trial to evaluate outcomes in patients receiving donor-derived CD19-specific chimeric antigen receptor (CAR) T cells for B-cell malignancy that relapsed or persisted after matched related allogeneic hemopoietic stem cell transplant. To overcome the cost and transgene-capacity limitations of traditional viral vectors, CAR T cells were produced using the piggyBac transposon system of genetic modification. Following CAR T-cell infusion, 1 patient developed a gradually enlarging retroperitoneal tumor due to a CAR-expressing CD4+ T-cell lymphoma. Screening of other patients led to the detection, in an asymptomatic patient, of a second CAR T-cell tumor in thoracic para-aortic lymph nodes. Analysis of the first lymphoma showed a high transgene copy number, but no insertion into typical oncogenes. There were also structural changes such as altered genomic copy number and point mutations unrelated to the insertion sites. Transcriptome analysis showed transgene promoter-driven upregulation of transcription of surrounding regions despite insulator sequences surrounding the transgene. However, marked global changes in transcription predominantly correlated with gene copy number rather than insertion sites. In both patients, the CAR T-cell-derived lymphoma progressed and 1 patient died. We describe the first 2 cases of malignant lymphoma derived from CAR gene-modified T cells. Although CAR T cells have an enviable record of safety to date, our results emphasize the need for caution and regular follow-up of CAR T recipients, especially when novel methods of gene transfer are used to create genetically modified immune therapies. This trial was registered at www.anzctr.org.au as ACTRN12617001579381., (© 2021 by The American Society of Hematology.)
- Published
- 2021
- Full Text
- View/download PDF
153. Development of a monoclonal antibody for the detection of anti-canine CD20 chimeric antigen receptor expression on canine CD20 chimeric antigen receptor-transduced T cells.
- Author
-
Sakai O, Ogino S, Tsukui T, Igase M, and Mizuno T
- Subjects
- Animals, Antibodies, Monoclonal, Antigens, CD20, Cell Line, Tumor, Dogs, Receptors, Antigen, T-Cell, T-Lymphocytes, Dog Diseases therapy, Lymphoma, B-Cell therapy, Lymphoma, B-Cell veterinary, Receptors, Chimeric Antigen
- Abstract
Chimeric antigen receptor (CAR) CAR-T cell therapy targeting CD20 can be a novel adoptive cell therapy for canine patients with B-cell malignancy. After injection of the CAR-T cells in vivo, monitoring circulating CAR-T cells is essential to prove in vivo persistence of CAR-T cells. In this study, we developed a novel monoclonal antibody against canine CD20 CAR, whose single-chain variable fragment was derived from the our previously reported anti-canine CD20 therapeutic antibody. Furthermore, we proved that this monoclonal antibody can detect therapeutic anti-canine CD20 chimeric antibody in the serum from healthy beagle dogs injected with the therapeutic antibody for safety study. This monoclonal antibody is a useful tool for monitoring both canine CD20-CAR-T cells and anti-canine CD20 therapeutic antibody for canine lymphoma.
- Published
- 2021
- Full Text
- View/download PDF
154. Regulatory hurdles for CAR T-cell therapy in Japan.
- Author
-
Nagai S
- Subjects
- Clinical Trials as Topic, Humans, Japan epidemiology, Lymphoma, B-Cell epidemiology, Lymphoma, B-Cell therapy, Marketing, Receptors, Chimeric Antigen therapeutic use, Treatment Outcome, Immunotherapy, Adoptive economics, Immunotherapy, Adoptive legislation & jurisprudence, Immunotherapy, Adoptive methods
- Published
- 2021
- Full Text
- View/download PDF
155. [Chimeric antigen receptor T cells].
- Author
-
Bories P and Ysebaert L
- Subjects
- Adenine analogs & derivatives, Adenine therapeutic use, Antibodies, Bispecific therapeutic use, Antigens, CD19 immunology, Antigens, Neoplasm immunology, Cell Engineering, Clinical Trials, Phase II as Topic, Genetic Engineering, Humans, Leukemia, Lymphocytic, Chronic, B-Cell immunology, Leukemia, Lymphocytic, Chronic, B-Cell therapy, Lymphoma, B-Cell immunology, Piperidines therapeutic use, T-Lymphocytes immunology, Lymphoma, B-Cell therapy, Receptors, Chimeric Antigen immunology, T-Lymphocytes transplantation
- Abstract
Chimeric antigen receptor T-cell (CAR T-cells) therapies which are genetically modified T lymphocyte targeting tumor antigens have modified therapeutic landscape in hematology. Aggressive B cells lymphoma are currently treated in daily practice with anti-CD19 CAR T. In indolent B cell lymphomas, their efficacy has been established by recent clinical trials. Longer follow-up evaluation is needed to determine their added value in a field where approved strategies already provide high long-term survival rates. They will also be challenged by another immunotherapy with bispecific antibodies. In chronic lymphoid leukemia, early phase trials have identified several limitations related to the immune context of this disease, but associations with targeted therapy like ibrutinib are very promising. In this moving therapeutic landscape, molecular and cellular engineering progress will increase the capacities of these new cellular-based therapies., (Copyright © 2021 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
156. Chimeric antigen receptor T-cells in New Zealand: challenges and opportunities.
- Author
-
Weinkove R, George P, Ruka M, Haira TH, and Giunti G
- Subjects
- Adolescent, Adult, Aged, Female, Health Equity, Humans, Male, Middle Aged, Native Hawaiian or Other Pacific Islander, Neoplasm Recurrence, Local, Neurotoxicity Syndromes etiology, Neurotoxicity Syndromes immunology, New Zealand, Receptors, Antigen, T-Cell immunology, Receptors, Chimeric Antigen immunology, Remission Induction, T-Lymphocytes immunology, Young Adult, Immunotherapy, Adoptive adverse effects, Immunotherapy, Adoptive methods, Lymphoma, B-Cell therapy, Lymphoma, Non-Hodgkin therapy, Receptors, Chimeric Antigen therapeutic use, T-Lymphocytes transplantation
- Abstract
Chimeric antigen receptor (CAR) T-cells are a personalised cell and gene therapy for cancer that are becoming an international standard of care for some refractory B-cell leukaemias, non-Hodgkin lymphomas and myeloma. A single CAR T-cell administration can result in durable complete response for some recipients. Domestic CAR T-cell manufacturing capability was established for Aotearoa New Zealand's first CAR T-cell trial (ENABLE, ClinicalTrials.gov NCT04049513). This article outlines CAR T-cell manufacturing and logistical considerations, with a focus on New Zealand's environment for this personalised cell and gene therapy. We discuss Māori engagement in CAR T-cell trial and clinical service design, and propose enhancing Māori guardianship (kaitiakitanga) over cells and genetic material through on-shore manufacture. Strategies to safely deliver CAR T-cells within New Zealand's healthcare system are outlined. Finally, we discuss challenges to, and opportunities for, widening CAR T-cell availability and assuring equity of access. Based on our experience, we consider Aotearoa New Zealand to be in an excellent position to develop and implement investigational and commercial CAR T-cell therapies in the future., Competing Interests: RW, PG, TH and GG are employees of the Malaghan Institute of Medical Research, which sponsors the ENABLE trial. The authors do not have proprietary or financial interests in the WZTL-002 CAR T-cell product.
- Published
- 2021
157. Invariant natural killer T-cell subsets have diverse graft-versus-host-disease-preventing and antitumor effects.
- Author
-
Maas-Bauer K, Lohmeyer JK, Hirai T, Ramos TL, Fazal FM, Litzenburger UM, Yost KE, Ribado JV, Kambham N, Wenokur AS, Lin PY, Alvarez M, Mavers M, Baker J, Bhatt AS, Chang HY, Simonetta F, and Negrin RS
- Subjects
- Animals, Epigenomics, Female, Gene Expression Profiling, Male, Mice, Graft vs Host Disease immunology, Graft vs Host Disease prevention & control, Graft vs Tumor Effect immunology, Lymphocyte Activation, Lymphoma, B-Cell immunology, Lymphoma, B-Cell therapy, Natural Killer T-Cells immunology, Neoplasms, Experimental immunology, Neoplasms, Experimental therapy
- Abstract
Invariant natural killer T (iNKT) cells are a T-cell subset with potent immunomodulatory properties. Experimental evidence in mice and observational studies in humans indicate that iNKT cells have antitumor potential as well as the ability to suppress acute and chronic graft-versus-host-disease (GVHD). Murine iNKT cells differentiate during thymic development into iNKT1, iNKT2, and iNKT17 sublineages, which differ transcriptomically and epigenomically and have subset-specific developmental requirements. Whether distinct iNKT sublineages also differ in their antitumor effect and their ability to suppress GVHD is currently unknown. In this work, we generated highly purified murine iNKT sublineages, characterized their transcriptomic and epigenomic landscape, and assessed specific functions. We show that iNKT2 and iNKT17, but not iNKT1, cells efficiently suppress T-cell activation in vitro and mitigate murine acute GVHD in vivo. Conversely, we show that iNKT1 cells display the highest antitumor activity against murine B-cell lymphoma cells both in vitro and in vivo. Thus, we report for the first time that iNKT sublineages have distinct and different functions, with iNKT1 cells having the highest antitumor activity and iNKT2 and iNKT17 cells having immune-regulatory properties. These results have important implications for the translation of iNKT cell therapies to the clinic for cancer immunotherapy as well as for the prevention and treatment of GVHD., (© 2021 by The American Society of Hematology.)
- Published
- 2021
- Full Text
- View/download PDF
158. Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell-directed therapies.
- Author
-
Ghione P, Gu JJ, Attwood K, Torka P, Goel S, Sundaram S, Mavis C, Johnson M, Thomas R, McWhite K, Darrall A, DeMarco J, Kostrewa J, Mohr A, Rivas L, Neiders M, Suresh L, Segal BH, Griffiths EA, Ramsperger V, Shen L, and Hernandez-Ilizaliturri FJ
- Subjects
- Adult, Aged, Aged, 80 and over, Antibodies, Viral biosynthesis, Antibodies, Viral blood, Antineoplastic Agents adverse effects, Antineoplastic Agents pharmacology, Antineoplastic Agents therapeutic use, B-Lymphocytes drug effects, Cancer Care Facilities, Cohort Studies, Female, Health Personnel, Hematopoietic Stem Cell Transplantation adverse effects, Humans, Immunoglobulin G biosynthesis, Immunoglobulin G blood, Immunoglobulin G immunology, Immunoglobulin M biosynthesis, Immunoglobulin M blood, Immunoglobulin M immunology, Immunotherapy, Adoptive adverse effects, Institutionalization, Lymphoma, B-Cell therapy, Lymphoma, T-Cell immunology, Lymphoma, T-Cell therapy, Male, Middle Aged, Multiple Myeloma immunology, Multiple Myeloma therapy, Nursing Homes, Patients, Prospective Studies, Antibodies, Viral immunology, Antigens, Viral immunology, B-Lymphocytes immunology, COVID-19 prevention & control, COVID-19 Vaccines immunology, Lymphoma, B-Cell immunology, SARS-CoV-2 immunology, Spike Glycoprotein, Coronavirus immunology, Vaccination
- Published
- 2021
- Full Text
- View/download PDF
159. Selection process and causes of non-eligibility for CD19 CAR-T cell therapy in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma in a European center.
- Author
-
Carpio C, Iacoboni G, Villacampa G, Catalá E, Bobillo S, Pérez A, Jiménez M, Segura L, Olivé M, Farriols A, Abrisqueta P, Valcárcel D, Carreras MJ, Bosch F, and Barba P
- Subjects
- Antigens, CD19, B-Lymphocytes, Cell- and Tissue-Based Therapy, Humans, Immunotherapy, Adoptive, Receptors, Antigen, T-Cell, Lymphoma, B-Cell therapy, Receptors, Chimeric Antigen genetics
- Published
- 2021
- Full Text
- View/download PDF
160. Evaluation of mid-term (6-12 months) neurotoxicity in B-cell lymphoma patients treated with CAR T cells: a prospective cohort study.
- Author
-
Maillet D, Belin C, Moroni C, Cuzzubbo S, Ursu R, Sirven-Villaros L, Di Blasi R, Thieblemont C, and Carpentier AF
- Subjects
- Antigens, CD19, Humans, Immunotherapy, Adoptive, Prospective Studies, T-Lymphocytes, Lymphoma, B-Cell therapy, Receptors, Chimeric Antigen
- Abstract
Background: Chimeric antigen receptor-modified T (CAR T) cells are profoundly changing the standard of care in B-cell malignancies. This new therapeutic class induces a significant number of acute neurotoxicity, but data regarding mid- and long-term neurological safety are scarce. We evaluated mid-term neurological safety, with special emphasis on cognitive functions, in a series of adults treated with CAR T cells., Methods: Patients treated in a single center with CD19-targeted CAR T cells for a relapsing B-cell lymphoma were prospectively followed up by neurologists. Before CAR T-cell infusion, all patients underwent neurological examinations with neuropsychological testing and filled out questionnaires assessing anxiety, depression, and cognitive complaints. Patients surviving without tumor progression were re-evaluated similarly, 6-12 months later., Results: In this prospective cohort of 56 consecutive adult patients treated with CAR T cells, 27 were eligible for mid-term evaluation (median time 7.6 months). Twelve patients developed an acute and reversible neurotoxicity with median duration time of 5.5 days. In all patients, neurological examination on mid-term evaluation was similar to baseline. In self-assessment questionnaires, 63% of patients reported clinically meaningful anxiety, depression, or cognitive difficulties at baseline, a number reduced to 44% at the time of mid-term evaluation. On cognitive assessments, no significant deterioration was found when compared to baseline, in any cognitive functions assessed (verbal and visual memory, executive functions, language, and praxis), even in patients who developed acute neurotoxicity., Conclusion: In this cohort of patients treated with CD19-targeted CAR T cells, we found no evidence for neurological or cognitive toxicity, 6-12 months after treatment., (© The Author(s) 2021. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2021
- Full Text
- View/download PDF
161. Primary Mediastinal B Cell Lymphoma in the Positron-Emission Tomography Era Executive Summary of the American Radium Society Appropriate Use Criteria.
- Author
-
Hoppe BS, Advani R, Milgrom SA, Bakst RL, Ballas LK, Dabaja BS, Flowers CR, Ha CS, Mansur DB, Metzger ML, Pinnix CC, Plastaras JP, Roberts KB, Smith SM, Terezakis SA, Kirwan JM, and Constine LS
- Subjects
- Humans, Lymphoma, B-Cell diagnostic imaging, Mediastinal Neoplasms diagnostic imaging, Radiotherapy Planning, Computer-Assisted, Lymphoma, B-Cell therapy, Mediastinal Neoplasms therapy, Positron Emission Tomography Computed Tomography methods
- Abstract
Purpose: Primary mediastinal B cell lymphoma (PMBCL) is a highly curable subtype of non-Hodgkin lymphoma that is diagnosed predominantly in adolescents and young adults. Consequently, long-term treatment-related morbidity is critical to consider when devising treatment strategies that include different chemoimmunotherapy strategies with or without radiation therapy. Furthermore, adaptive approaches using the end-of-chemotherapy (EOC) positron emission tomography (PET)/computed tomography (CT) scanning may help to determine which patients may benefit from additional therapies. We aimed to develop evidence-based guidelines for treating these patients., Methods and Materials: We conducted a systematic review in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guideline using the PubMed database. The ARS expert committee, composed of radiation oncologists, hematologists, and pediatric oncologists, developed consensus guidelines using the modified Delphi framework., Results: Nine studies met the full criteria for inclusion based on reporting outcomes on patients with primary mediastinal B cell lymphoma with EOC PET/CT response scored with the 5-point Deauville scale. These studies formed the evidence for these guidelines in managing patients with PMBCL according to the EOC PET response, including after a 5-point Deauville scale of 1 to 3, 4, or 5, and for patients with relapsed and refractory disease. The expert group also developed guidance on radiation simulation, treatment planning, and plan evaluation based on expert opinion., Conclusions: Various treatment approaches exist in the management of PMBCL, including different chemoimmunotherapy regimens, the use of consolidative radiation therapy, and adaptive approaches based on EOC PET/CT response. These guidelines can be used by practitioners to provide appropriate treatment according to different disease scenarios., (Copyright © 2021 Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
162. CD19/CD22 Dual-Targeted CAR T-cell Therapy for Relapsed/Refractory Aggressive B-cell Lymphoma: A Safety and Efficacy Study.
- Author
-
Wei G, Zhang Y, Zhao H, Wang Y, Liu Y, Liang B, Wang X, Xu H, Cui J, Wu W, Zhao K, Nagler A, Chang AH, Hu Y, and Huang H
- Subjects
- Animals, Antigenic Drift and Shift, Antigens, CD19 immunology, Cell Line, Female, Humans, Immunotherapy, Adoptive, Mice, Progression-Free Survival, Sialic Acid Binding Ig-like Lectin 2, T-Lymphocytes immunology, Xenograft Model Antitumor Assays, Hematopoietic Stem Cell Transplantation, Lymphoma, B-Cell therapy, Neoplasm Recurrence, Local therapy, Receptors, Chimeric Antigen
- Abstract
Chimeric antigen receptor (CAR) T-cell therapies that target either CD19 or CD22 alone have potent antilymphoma effects. However, antigen escape-mediated relapse often occurs. CAR T cells targeting both CD19 and CD22 may overcome this limitation. In this study, we developed bispecific CAR T cells simultaneously recognizing CD19- and CD22-expressing targets and assessed their safety and efficacy profiles in patients with relapsed/refractory aggressive B-cell lymphoma. Twenty-four patients were screened, and 16 were found eligible for the study. CAR T-cell-associated toxicities were recorded. Responses, overall survival (OS), and progression-free survival (PFS) were assessed. Of the 16 eligible patients, 14 (87.5%) achieved objective response and 10 (62.5%) achieved complete response (CR). The 2-year OS and PFS rates were 77.3% and 40.2%, respectively. Achieving CR ( P = 0.046) and the number of prior chemotherapy lines ( n = 2; P = 0.047) were independent prognostic factors associated with favorable PFS. The 2-year OS and PFS among patients who achieved CR were higher than among those who did not ( P = 0.015 and P < 0.001, respectively). The 2-year PFS among patients who received two prior lines of chemotherapy was higher than that among patients who received more than two lines of chemotherapy ( P = 0.049); OS did not differ between the groups. Severe grade 4 cytokine-release syndrome (CRS) was observed in 1 patient; 4 and 11 patients had grades 1 and 2 CRS, respectively. No patients developed neurotoxicity. CD19/CD22 dual-targeted CAR T cells may be a safe, potent antilymphoma cell-based targeted immunotherapy., (©2021 American Association for Cancer Research.)
- Published
- 2021
- Full Text
- View/download PDF
163. Targeting the tumor microenvironment in B-cell lymphoma: challenges and opportunities.
- Author
-
Liu Y, Zhou X, and Wang X
- Subjects
- Animals, Antineoplastic Agents pharmacology, Antineoplastic Agents therapeutic use, B-Lymphocytes drug effects, B-Lymphocytes immunology, B-Lymphocytes pathology, Drug Discovery methods, Humans, Immunotherapy methods, Lymphoma, B-Cell immunology, Lymphoma, B-Cell pathology, Molecular Targeted Therapy methods, Lymphoma, B-Cell therapy, Tumor Escape drug effects, Tumor Microenvironment drug effects
- Abstract
B-cell lymphoma is a group of hematological malignancies with high clinical and biological heterogeneity. The pathogenesis of B-cell lymphoma involves a complex interaction between tumor cells and the tumor microenvironment (TME), which is composed of stromal cells and extracellular matrix. Although the roles of the TME have not been fully elucidated, accumulating evidence implies that TME is closely relevant to the origination, invasion and metastasis of B-cell lymphoma. Explorations of the TME provide distinctive insights for cancer therapy. Here, we epitomize the recent advances of TME in B-cell lymphoma and discuss its function in tumor progression and immune escape. In addition, the potential clinical value of targeting TME in B-cell lymphoma is highlighted, which is expected to pave the way for novel therapeutic strategies., (© 2021. The Author(s).)
- Published
- 2021
- Full Text
- View/download PDF
164. TGF-β/IL-7 Chimeric Switch Receptor-Expressing CAR-T Cells Inhibit Recurrence of CD19-Positive B Cell Lymphoma.
- Author
-
Noh KE, Lee JH, Choi SY, Jung NC, Nam JH, Oh JS, Song JY, Seo HG, Wang Y, Lee HS, and Lim DS
- Subjects
- Animals, Cells, Cultured, Female, Humans, Immunotherapy, Adoptive, Interleukin-7 metabolism, K562 Cells, Lymphoma, B-Cell immunology, Mice, Mice, Inbred NOD, Mice, SCID, Neoplasm Recurrence, Local immunology, Receptors, Chimeric Antigen metabolism, Signal Transduction, Transforming Growth Factor beta metabolism, Treatment Outcome, Xenograft Model Antitumor Assays, Antigens, CD19 immunology, Interleukin-7 genetics, Lymphoma, B-Cell therapy, Neoplasm Recurrence, Local therapy, Single-Chain Antibodies metabolism, Transforming Growth Factor beta genetics
- Abstract
Chimeric antigen receptor (CAR)-T cells are effective in the treatment of hematologic malignancies but have shown limited efficacy against solid tumors. Here, we demonstrated an approach to inhibit recurrence of B cell lymphoma by co-expressing both a human anti-CD19-specific single-chain variable fragment (scFv) CAR (CD19 CAR) and a TGF-β/IL-7 chimeric switch receptor (tTRII-I7R) in T cells (CD19 CAR-tTRII-I7R-T cells). The tTRII-I7R was designed to convert immunosuppressive TGF-β signaling into immune-activating IL-7 signaling. The effect of TGF-β on CD19 CAR-tTRII-I7R-T cells was assessed by western blotting. Target-specific killing by CD19 CAR-tTRII-I7R-T cells was evaluated by Eu-TDA assay. Daudi tumor-bearing NSG (NOD/SCID/IL2Rγ
-/- ) mice were treated with CD19 CAR-tTRII-I7R-T cells to analyze the in vivo anti-tumor effect. In vitro, CD19 CAR-tTRII-I7R-T cells had a lower level of phosphorylated SMAD2 and a higher level of target-specific cytotoxicity than controls in the presence of rhTGF-β1. In the animal model, the overall survival and recurrence-free survival of mice that received CD19 CAR-tTRII-I7R-T cells were significantly longer than in control mice. These findings strongly suggest that CD19 CAR-tTRII-I7R-T cell therapy provides a new strategy for long-lasting, TGF-β-resistant anti-tumor effects against B cell lymphoma, which may lead ultimately to increased clinical efficacy.- Published
- 2021
- Full Text
- View/download PDF
165. CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial.
- Author
-
Spiegel JY, Patel S, Muffly L, Hossain NM, Oak J, Baird JH, Frank MJ, Shiraz P, Sahaf B, Craig J, Iglesias M, Younes S, Natkunam Y, Ozawa MG, Yang E, Tamaresis J, Chinnasamy H, Ehlinger Z, Reynolds W, Lynn R, Rotiroti MC, Gkitsas N, Arai S, Johnston L, Lowsky R, Majzner RG, Meyer E, Negrin RS, Rezvani AR, Sidana S, Shizuru J, Weng WK, Mullins C, Jacob A, Kirsch I, Bazzano M, Zhou J, Mackay S, Bornheimer SJ, Schultz L, Ramakrishna S, Davis KL, Kong KA, Shah NN, Qin H, Fry T, Feldman S, Mackall CL, and Miklos DB
- Subjects
- Adult, Aged, Disease Progression, Humans, Lymphoma, B-Cell immunology, Middle Aged, Recurrence, Antigens, CD19 immunology, Immunotherapy, Adoptive adverse effects, Lymphoma, B-Cell therapy, Sialic Acid Binding Ig-like Lectin 2 immunology
- Abstract
Despite impressive progress, more than 50% of patients treated with CD19-targeting chimeric antigen receptor T cells (CAR19) experience progressive disease. Ten of 16 patients with large B cell lymphoma (LBCL) with progressive disease after CAR19 treatment had absent or low CD19. Lower surface CD19 density pretreatment was associated with progressive disease. To prevent relapse with CD19
- or CD19lo disease, we tested a bispecific CAR targeting CD19 and/or CD22 (CD19-22.BB.z-CAR) in a phase I clinical trial ( NCT03233854 ) of adults with relapsed/refractory B cell acute lymphoblastic leukemia (B-ALL) and LBCL. The primary end points were manufacturing feasibility and safety with a secondary efficacy end point. Primary end points were met; 97% of products met protocol-specified dose and no dose-limiting toxicities occurred during dose escalation. In B-ALL (n = 17), 100% of patients responded with 88% minimal residual disease-negative complete remission (CR); in LBCL (n = 21), 62% of patients responded with 29% CR. Relapses were CD19-/lo in 50% (5 out of 10) of patients with B-ALL and 29% (4 out of 14) of patients with LBCL but were not associated with CD22-/lo disease. CD19/22-CAR products demonstrated reduced cytokine production when stimulated with CD22 versus CD19. Our results further implicate antigen loss as a major cause of CAR T cell resistance, highlight the challenge of engineering multi-specific CAR T cells with equivalent potency across targets and identify cytokine production as an important quality indicator for CAR T cell potency., (© 2021. The Author(s).)- Published
- 2021
- Full Text
- View/download PDF
166. Pembrolizumab for refractory primary mediastinal B-cell lymphoma with central nervous system involvement.
- Author
-
de-la-Fuente C, Nuñez F, Cortés-Romera M, Franch-Sarto M, Ribera JM, and Sancho JM
- Subjects
- Adult, Allografts, B7-H1 Antigen antagonists & inhibitors, B7-H1 Antigen genetics, B7-H1 Antigen metabolism, Central Nervous System Neoplasms genetics, Central Nervous System Neoplasms metabolism, Central Nervous System Neoplasms pathology, Chromosomes, Human, Pair 9 genetics, Chromosomes, Human, Pair 9 metabolism, Female, Humans, Lymphoma, B-Cell genetics, Lymphoma, B-Cell metabolism, Lymphoma, B-Cell pathology, Mediastinal Neoplasms genetics, Mediastinal Neoplasms metabolism, Mediastinal Neoplasms pathology, Membrane Proteins antagonists & inhibitors, Membrane Proteins genetics, Membrane Proteins metabolism, Neoplasm Proteins antagonists & inhibitors, Neoplasm Proteins genetics, Neoplasm Proteins metabolism, Translocation, Genetic, Tumor Suppressor Proteins antagonists & inhibitors, Tumor Suppressor Proteins genetics, Tumor Suppressor Proteins metabolism, Antibodies, Monoclonal, Humanized administration & dosage, Central Nervous System Neoplasms therapy, Lymphoma, B-Cell therapy, Mediastinal Neoplasms therapy, Stem Cell Transplantation
- Abstract
Primary mediastinal large B-cell lymphoma (PMBCL) is a rare aggressive B-cell lymphoma characterized by the frequent presence of amplification and translocation events at 9p24.1, resulting in the expression of the programmed cell death-1 (PD-1) ligands PD-L1 and PD-L2. Pembrolizumab, a humanized anti-PD-1 monoclonal antibody, binds PD-1 and blocks this interaction, enhancing the activity of the immune system against tumor cells, and has shown activity in PMBCL and in some cases of primary and secondary central nervous system (CNS) lymphoma. We report the case of a 40-year-old woman diagnosed with relapsed PMBCL and secondary CNS involvement who responded to pembrolizumab monotherapy, allowing for a later allogeneic stem cell transplant., (© 2020 John Wiley & Sons Ltd.)
- Published
- 2021
- Full Text
- View/download PDF
167. Prognostic Impact of 18F-FDG PET/CT in Patients With Aggressive B-Cell Lymphoma Treated With Anti-CD19 Chimeric Antigen Receptor T Cells.
- Author
-
Sesques P, Tordo J, Ferrant E, Safar V, Wallet F, Dhomps A, Brisou G, Bouafia F, Karlin L, Ghergus D, Golfier C, Lequeu H, Lazareth A, Vercasson M, Hospital-Gustem C, Schwiertz V, Choquet M, Sujobert P, Novelli S, Mialou V, Hequet O, Carras S, Fouillet L, Lebras L, Guillermin Y, Leyronnas C, Cavalieri D, Janier M, Ghesquières H, Salles G, and Bachy E
- Subjects
- Adult, Aged, Glycolysis, Humans, Lymphoma, B-Cell immunology, Lymphoma, B-Cell pathology, Male, Middle Aged, Prognosis, Retrospective Studies, Tumor Burden, Fluorodeoxyglucose F18, Immunotherapy, Adoptive, Lymphoma, B-Cell diagnostic imaging, Lymphoma, B-Cell therapy, Positron Emission Tomography Computed Tomography, Receptors, Chimeric Antigen immunology, T-Lymphocytes immunology
- Abstract
Purpose of the Report: We aimed to evaluate the role of 18F-FDG PET/CT in predicting patient outcome following chimeric antigen receptor T (CAR T) cells infusion in aggressive B-cell lymphoma., Methods: 18F-FDG PET/CT data before leukapheresis, before CAR T-cell infusion and 1 month (M1) after CAR T-cell infusion, from 72 patients were retrospectively analyzed. SUVmax, total lesion glycolysis (TLG), metabolic tumor volume (MTV), and parameters describing tumor kinetics were calculated for each 18F-FDG PET/CT performed. The aim was to evaluate the prognostic value of 18F-FDG PET/CT metabolic parameters for predicting progression-free survival (PFS) and overall survival (OS) following CAR T-cell therapy., Results: Regarding PFS, ∆MTVpre-CAR and ∆TLGpre-CAR were found to be more discriminating compared with metabolic parameters at preinfusion. Median PFS in patients with a ∆MTVpre-CAR of less than 300% was 6.8 months (95% confidence interval [CI], 2.8 months to not reached) compared with 2.8 months (95% CI, 0.9-3.0 months) for those with a value of 300% or greater (P = 0.004). Likewise, median PFS in patients with ∆TLGpre-CAR of less than 420% was 6.8 months (95% CI, 2.8 months to not reached) compared with 2.7 months (95% CI, 1.3-3.0 months) for those with a value of 420% or greater (P = 0.0148). Regarding OS, metabolic parameters at M1 were strongly associated with subsequent outcome. SUVmax at M1 with a cutoff value of 14 was the most predictive parameter in multivariate analysis, outweighing other clinicobiological variables (P < 0.0001)., Conclusions: Disease metabolic volume kinetics before infusion of CAR T cells seems to be superior to initial tumor bulk itself for predicting PFS. For OS, SUVmax at M1 might adequately segregate patients with different prognosis., Competing Interests: Conflicts of interest and sources of funding: P. Sesques: honoraria, advisory/consultancy from Novartis and Kite/Gilead; F.W.: honoraria, advisory/consultancy from Novartis and Kite/Gilead; V. Schwiertz: honoraria, advisory/consultancy from Kite/Gilead and Novartis; G.S.: advisory board/consulting for Gilead, Kite, Novartis; E.B.: honoraria, consultancy from Gilead, Novartis. The other authors have none declared., (Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
168. Risk of HBV Reactivation in Patients With Resolved HBV Infection Receiving Anti-CD19 Chimeric Antigen Receptor T Cell Therapy Without Antiviral Prophylaxis.
- Author
-
Li P, Zhou L, Ye S, Zhang W, Wang J, Tang X, Liu J, Xu Y, Qian W, and Liang A
- Subjects
- Adolescent, Adult, Antigens, CD19 immunology, Cells, Cultured, Child, Child, Preschool, Female, Hepatitis B immunology, Humans, Infant, Lymphoma, B-Cell immunology, Male, Middle Aged, Virus Activation, Young Adult, Antiviral Agents therapeutic use, Hepatitis B therapy, Hepatitis B virus physiology, Immunotherapy, Adoptive methods, Lymphoma, B-Cell therapy
- Abstract
Background: Chimeric antigen receptor (CAR) T-cell therapy has emerged as a novel treatment modality for hematologic malignancies and is predicted to experience widespread use in the near future. However, not all risks associated with this novel approach are well defined. There are few data in the risk of HBV reactivation and limited experience in management in patients with resolved HBV infection who undergo CAR-T cell therapy., Methods: We performed a post-hoc analysis of a prospective clinical trial of anti-CD19 CAR-T (CART19) cell therapy in patients with relapsed or refractory (r/r) B-cell malignancies, and aimed at exploring the actual risk of HBV reactivation in a cohort of patients with resolved HBV infection receiving CART19 cell therapy in the absence of antiviral prophylaxis., Results: In this study, we investigated the risk of HBV reactivation after CART19 cell therapy in 30 consecutive patients with B-cell malignancies and resolved HBV infection without antiviral prophylaxis, in the Tongji Hospital of Tongji University. In this cohort, two patients developed HBV reactivation 2 months and 14 months after CAR-T cell infusion, respectively, the latter of whom developed severe hepatitis. These findings showed that the incidence of HBV reactivation was 6.67% (95% CI, 0.8-22.1). Specifically, none of the 21 patients who were HBsAb positive (0.0%) versus two of nine patients who were HBsAb negative (22.2%) experienced HBV reactivation (p = 0.03), suggesting HbsAb seronegativity at baseline is a possible risk factor in this population. Although use of tocilizumab or corticosteroids has been associated with increased risk of HBV reactivation, none of the patients who received these agents had HBV reactivation in this study., Conclusion: This is the first and largest study to assess the true incidence of HBV reactivation in patients with resolved HBV infection receiving CART19 cell therapy without antiviral prophylaxis. This study highlights that this population are at risk of developing HBV reactivation and indicates that close monitoring of HBV DNA is required in the absence of antiviral prophylaxis. In addition, antiviral prophylaxis is recommended in the HBsAb-negative subpopulation., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2021 Li, Zhou, Ye, Zhang, Wang, Tang, Liu, Xu, Qian and Liang.)
- Published
- 2021
- Full Text
- View/download PDF
169. [Analysis of local reactions and efficacy of CD19 chimeric antigen receptor-modified T cells therapy in recurrent/refractory B-cell lymphoma with >7.5 cm lesions].
- Author
-
Li Q, Deng HB, Liu MJ, Lyu CC, Zhu HB, Wang J, Jiang YL, Pu YD, Jiang YY, Li W, and Deng Q
- Subjects
- Antigens, CD19, Humans, Neoplasm Recurrence, Local, T-Lymphocytes, Lymphoma, B-Cell therapy, Receptors, Chimeric Antigen
- Abstract
Objective: To observe the local reactions and efficacy of CD19 CAR-T therapy in recurrence/refractory B-cell non-Hodgkin's lymphoma (R/R NHL) patients with >7.5 cm lesions. Methods: 32 R/R NHL patients with >7.5 cm lesions were enrolled and injected with CD19 CAR-T cells. Flow cytometry was used to detect and observe the amplification of CD19 CAR-T cells in vivo. Enzyme-linked immunosorbent assay (ELISA) was used to detect cytokines in peripheral blood of patients. The side effects of CD19 CAR-T cell therapy included systemic side effects and local reactions of tumor. The local side effects were observed by Ultrasound, Computed tomography and Magnetic resonance imaging. Treatment options included glucocorticoid, interleukin-6 antibody and drainage of exudate. Overall response rate (ORR) and overall survival rate (OS) were observed. Results: ①Among the 32 patients, CR (40.63%) , PR (31.25%) and ORR (71.88%) were 13, 10 and 23, respectively. ②In all 23 patients received ORR, 13 patients had grade 1-2 CRS, while 10 patients had grade 3-4 CRS. All the 9 patients in the SD+PD group had grade 1-2 CRS ( P =0.030) . ③A total of 15 patients with tumor local reactions, included 9 patients with CR, 5 patients with PR and 1 patient with SD. The local reactions of the tumor included that the diameter of the superficial lesions increased with redness, swelling and heat pain. The deep lesions presented abdominal pain, abdominal distension, suffocation and local pain, and burning of the tumor. The deep lesions were enlarged or accompanied by local edema. The local exudative lesions were found in the abdominal cavity and pleural cavity. ④ Peak proportion of CD19 CAR-T cells in ORR group was higher than that of in SD+PD group[16.8% (5.3%-48.2%) vs 2.9% (1.5%-5.7%) , z =-4.297, P <0.001]. The peak proportion of CD19 CAR-T cells in ORR group with local reactions was higher than that of in patients without local reactions [22.2% (10.5%-48.2%) vs 12.6% (5.3%-21.6%) , z =-3.213, P =0.001]. The peak proportion of CD19 CAR-T cells in multiple lesion group was higher than that of in single lesion group [35.8% (1.5%-48.2%) vs 16.8% (10.5%-18.5%) , z =-2.023, P =0.040]. ⑤Occurrence of local reactions and tumor shrinkage time were both delayed compared with systemic side effects. ⑥In the ORR group, the OS of patients with tumor local reactions was longer than that of patients without tumor local reactions, but there was no difference in the two groups (75% vs 34.6%, P =0.169) . Conclusions: CD19 CAR-T cell therapy in R/R NHL patients with >7.5 cm lesions might cause tumor local reactions later than systemic side effects. Clinicaltrial:: ChiCTR1800018059.
- Published
- 2021
- Full Text
- View/download PDF
170. Case Report: Refractory Cryptosporidiosis after CAR T-Cell Therapy for Lymphoma.
- Author
-
Trottier CA, Yen CF, Malvar G, Arnason J, Avigan DE, and Alonso CD
- Subjects
- Aged, 80 and over, Diarrhea etiology, Female, Humans, Immunocompromised Host, Lymphoma, B-Cell complications, Cryptosporidiosis etiology, Immunotherapy, Adoptive, Lymphoma, B-Cell therapy
- Abstract
Cryptosporidial diarrhea is uncommon in immunocompetent individuals, more often seen in severely immunocompromised patients. Severe refractory cases have been described in patients with HIV/AIDS before the advent of modern antiretroviral therapy due to an inability to mount an adequate cellular immune response. We describe an 85-year-old patient post-chimeric antigen receptor T-cell therapy relapsed lymphoma who developed refractory Cryptosporidium spp. diarrhea in the setting of persistent CD4+ cytopenia. Despite receiving multiple antiparasitic agents, including failure of a prolonged course of nitazoxanide, the patient experienced persistent symptoms for 9 months with repeatedly positivity stool Cryptosporidium spp. direct fluorescent antibody (DFA) test. We highlight this case of refractory Cryptosporidium spp. and the importance of recognizing the pathogen in a non-HIV-infected immunosuppressed host.
- Published
- 2021
- Full Text
- View/download PDF
171. Ibrutinib improves the efficacy of anti-CD19-CAR T-cell therapy in patients with refractory non-Hodgkin lymphoma.
- Author
-
Liu M, Deng H, Mu J, Li Q, Pu Y, Jiang Y, Deng Q, and Qian Z
- Subjects
- Adenine therapeutic use, Adult, Aged, Combined Modality Therapy methods, Disease Progression, Drug Resistance, Neoplasm, Female, Humans, Immunotherapy, Adoptive adverse effects, Interleukin-6 blood, Interleukin-8 blood, Lymphoma, B-Cell blood, Lymphoma, B-Cell therapy, Lymphoma, Follicular blood, Lymphoma, Large B-Cell, Diffuse blood, Lymphoma, Large B-Cell, Diffuse therapy, Lymphoma, Mantle-Cell blood, Male, Middle Aged, Receptors, Interleukin-2 blood, Remission Induction methods, Retreatment, Treatment Outcome, Adenine analogs & derivatives, Immunotherapy, Adoptive methods, Lymphoma, Follicular therapy, Lymphoma, Mantle-Cell therapy, Piperidines therapeutic use, Receptors, Chimeric Antigen genetics, Salvage Therapy
- Abstract
The efficacy and side effects of the second-time humanized CD19 chimeric antigen receptor (CD19-CAR) T-cell therapy after unsuccessful first-time anti-CD19-CAR T-cell therapy and subsequent ibrutinib salvage treatment were observed in patients with refractory B-cell lymphoma. In our study, 3 patients with refractory mantle cell lymphoma (MCL) and 4 patients with refractory follicular lymphoma (FL) reached stable disease (SD), partial remission (PR), or progression of disease (PD) after first-time humanized anti-CD19-CAR T-cell therapy. They received ibrutinib as a salvage treatment and kept an SD in the following 7-16 mo, but their disease progressed again during ibrutinib salvage treatment. All 7 patients received a second-time humanized anti-CD19-CAR T-cell therapy, which was the same as their first-time anti-CD19-CAR T-cell therapy. In total, 3 MCL patients and 3 FL patients reached complete response (CR) with the second-time anti-CD19-CAR T-cell therapy combined with ibrutinib, whereas 1 FL patient reached PR. There were no differences in the transduction efficiency and proliferation between the 2 instances of anti-CD19-CAR T-cell therapy. However, the second-time anti-CD19-CAR T-cell therapy led to higher peaks of anti-CD19-CAR T cells and anti-CD19-CAR gene copies, but also to higher grades of cytokine release syndrome (CRS) and more serious hematological toxicity. The successful outcome of the second-time anti-CD19-CAR T-cell therapy might suggest that the previous ibrutinib treatment improved the activities of anti-CD19-CAR T cells., (© 2021 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.)
- Published
- 2021
- Full Text
- View/download PDF
172. Pretransplantation and posttransplantation considerations in the oral healthcare of a patient with non-Hodgkin B-cell lymphoma: a case report.
- Author
-
Teicher R and Henschel M
- Subjects
- Delivery of Health Care, Dentists, Humans, Neoplasm Recurrence, Local, Professional Role, Lymphoma, B-Cell therapy, Lymphoma, Non-Hodgkin
- Abstract
Dental practitioners must be comfortable with treating medically compromised patients, including those with cancer. In particular, dental practitioners must be aware of the comorbidities of non-Hodgkin lymphoma in order to treat patients with an appropriate standard of care. This case report describes the oral healthcare of a patient whose recurrent non-Hodgkin lymphoma created a degree of medical complexity that required a unique treatment path. As with many patients with non-Hodgkin lymphoma, the patient's compromised systemic health ultimately contributed to the deterioration of oral health, which in turn perpetuated the deleterious systemic concerns. As a result, both intensive medical and dental interventions were required to salvage the health of the patient. Secondary to the comprehensive medical treatment for managing the patient's cancer, there are several considerations that dentists must consider. This article explores those pretreatment and posttreatment considerations in the context of rehabilitative dentistry.
- Published
- 2021
173. Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial.
- Author
-
Hutchings M, Morschhauser F, Iacoboni G, Carlo-Stella C, Offner FC, Sureda A, Salles G, Martínez-Lopez J, Crump M, Thomas DN, Morcos PN, Ferlini C, Bröske AE, Belousov A, Bacac M, Dimier N, Carlile DJ, Lundberg L, Perez-Callejo D, Umaña P, Moore T, Weisser M, and Dickinson MJ
- Subjects
- Adult, Aged, Aged, 80 and over, Antibodies, Bispecific immunology, Antibodies, Bispecific pharmacokinetics, Antigens, CD20 immunology, Antineoplastic Agents, Immunological administration & dosage, Antineoplastic Agents, Immunological immunology, Antineoplastic Agents, Immunological pharmacokinetics, Female, Humans, Lymphoma, B-Cell immunology, Male, Middle Aged, T-Lymphocytes drug effects, T-Lymphocytes immunology, Young Adult, Antibodies, Bispecific administration & dosage, Lymphoma, B-Cell therapy
- Abstract
Purpose: Glofitamab is a T-cell-engaging bispecific antibody possessing a novel 2:1 structure with bivalency for CD20 on B cells and monovalency for CD3 on T cells. This phase I study evaluated glofitamab in relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL). Data for single-agent glofitamab, with obinutuzumab pretreatment ( Gpt ) to reduce toxicity, are presented., Methods: Seven days before the first dose of glofitamab (0.005-30 mg), all patients received 1,000 mg Gpt . Dose-escalation steps were determined using a Bayesian continuous reassessment method with overdose control. Primary end points were safety, pharmacokinetics, and the maximum tolerated dose of glofitamab., Results: Following initial single-patient cohorts, 171 patients were treated within conventional multipatient cohorts and received at least one dose of glofitamab. This trial included heavily pretreated patients with R/R B-NHL; most were refractory to prior therapy (155; 90.6%) and had received a median of three prior therapies. One hundred and twenty-seven patients (74.3%) had diffuse large B-cell lymphoma, transformed follicular lymphoma, or other aggressive histology, and the remainder had indolent lymphoma subtypes. Five (2.9%) patients withdrew from treatment because of adverse events. Cytokine release syndrome occurred in 86 of 171 (50.3%) patients (grade 3 or 4: 3.5%); two (1.2%) patients experienced grade 3, transient immune effector cell-associated neurotoxicity syndrome-like symptoms. The overall response rate was 53.8% (complete response [CR], 36.8%) among all doses and 65.7% (CR, 57.1%) in those dosed at the recommended phase II dose. Of 63 patients with CR, 53 (84.1%) have ongoing CR with a maximum of 27.4 months observation., Conclusion: In patients with predominantly refractory, aggressive B-NHL, glofitamab showed favorable activity with frequent and durable CRs and a predictable and manageable safety profile., Competing Interests: Martin HutchingsConsulting or Advisory Role: Takeda, Roche, GenmabResearch Funding: Celgene, Genmab, Roche, Takeda, Novartis Franck MorschhauserConsulting or Advisory Role: Roche/Genentech, Gilead Sciences, Celgene, Bristol Myers Squibb, AbbVie, Epizyme, ServierSpeakers' Bureau: RocheExpert Testimony: Roche/Genentech Gloria IacoboniHonoraria: Gilead Sciences, Novartis, Roche/Genentech, Celgene/Bristol Myers Squibb, JanssenConsulting or Advisory Role: Novartis, Celgene/Bristol Myers Squibb, Gilead SciencesTravel, Accommodations, Expenses: Gilead Sciences, Novartis, Celgene/Bristol Myers Squibb Carmelo Carlo-StellaHonoraria: Bristol Myers Squibb, Merck Sharp & Dohme, Janssen Oncology, AstraZeneca, Celgene, Takeda, Incyte, Gilead SciencesConsulting or Advisory Role: Sanofi, ADC Therapeutics, Roche, Karyopharm Therapeutics, Celgene/Bristol Myers Squibb, IncyteResearch Funding: ADC Therapeutics, Sanofi, RocheTravel, Accommodations, Expenses: Roche, Janssen, Takeda, ADC Therapeutics Anna SuredaHonoraria: Takeda, Bristol Myers Squibb, Merck Sharp & Dohme, Celgene, Janssen, Sanofi, Roche, Novartis, Gilead Sciences, Janssen-CilagConsulting or Advisory Role: Takeda, Bristol Myers Squibb, Gilead Sciences, Celgene, Janssen, NovartisSpeakers' Bureau: TakedaOther Relationship: Sanofi, Takeda, Roche, Celgene, Gilead Sciences Gilles SallesHonoraria: Roche/Genentech, Janssen, Celgene, Gilead Sciences, Novartis, AbbVie, MorphoSysConsulting or Advisory Role: Roche/Genentech, Gilead Sciences, Janssen, Celgene, Novartis, MorphoSys, Epizyme, Alimera Sciences, Genmab, Debiopharm Group, Velosbio, Bristol Myers Squibb, BeiGene, Incyte, Miltenyi Biotec Joaquín Martínez-LopezSpeakers' Bureau: Roche, Janssen-Cilag, BMSiResearch Funding: Astellas Pharma, Bristol Myers Squibb Michael CrumpHonoraria: Gilead Sciences, Servier/PfizerConsulting or Advisory Role: Servier, Gilead Sciences, Novartis Canada Pharmaceuticals IncResearch Funding: Roche Canada Denise N. ThomasEmployment: Roche TCRC, Genmab, Cellectis Peter N. MorcosEmployment: Roche/Genentech, BayerStock and Other Ownership Interests: Roche/Genentech, Bayer Cristiano FerliniEmployment: Roche/Genentech, AstraZenecaStock and Other Ownership Interests: AstraZeneca, Roche Ann-Marie E. BröskeEmployment: RocheStock and Other Ownership Interests: Roche, BioNTech AG Anton BelousovEmployment: Roche Marina BacacEmployment: RocheStock and Other Ownership Interests: RocheResearch Funding: RochePatents, Royalties, Other Intellectual Property: Coinventor in Roche patentsTravel, Accommodations, Expenses: Roche Natalie DimierEmployment: RocheStock and Other Ownership Interests: RocheTravel, Accommodations, Expenses: Roche David J. CarlileEmployment: Roche, AstraZenecaStock and Other Ownership Interests: AstraZeneca, Roche Linda LundbergEmployment: F. Hoffmann LaRocheStock and Other Ownership Interests: F. Hoffmann LaRoche David Perez-CallejoEmployment: RocheStock and Other Ownership Interests: Roche Pablo UmañaEmployment: RocheLeadership: RocheStock and Other Ownership Interests: RochePatents, Royalties, Other Intellectual Property: Co-inventor in Roche-owned patents on glofitamab and obinutuzumabTravel, Accommodations, Expenses: Roche Tom MooreEmployment: RocheStock and Other Ownership Interests: RocheTravel, Accommodations, Expenses: Roche Martin WeisserEmployment: RocheStock and Other Ownership Interests: RochePatents, Royalties, Other Intellectual Property: I hold patents for biomarkers and drug combinations. These are not related to the present study. I do not receive royalties Michael J. DickinsonHonoraria: Roche, Amgen, MSD, Janssen, Bristol Myers Squibb, NovartisConsulting or Advisory Role: Novartis, Bristol Myers Squibb, Gilead Sciences, Roche, JanssenSpeakers' Bureau: NovartisResearch Funding: Novartis, Roche, Takeda, Celgene, MSDTravel, Accommodations, Expenses: RocheNo other potential conflicts of interest were reported.
- Published
- 2021
- Full Text
- View/download PDF
174. Antibodies against vaccine-preventable infections after CAR-T cell therapy for B cell malignancies.
- Author
-
Walti CS, Krantz EM, Maalouf J, Boonyaratanakornkit J, Keane-Candib J, Joncas-Schronce L, Stevens-Ayers T, Dasgupta S, Taylor JJ, Hirayama AV, Bar M, Gardner RA, Cowan AJ, Green DJ, Boeckh MJ, Maloney DG, Turtle CJ, and Hill JA
- Subjects
- Adolescent, Adult, Aged, Antigens, CD19, B-Cell Maturation Antigen, Child, Child, Preschool, Cross-Sectional Studies, Female, Humans, Infant, Leukemia, Lymphocytic, Chronic, B-Cell therapy, Male, Middle Aged, Multiple Myeloma therapy, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma therapy, Prospective Studies, Vaccine-Preventable Diseases immunology, Young Adult, Agammaglobulinemia immunology, Antibodies, Bacterial immunology, Antibodies, Viral immunology, Immunity, Humoral immunology, Immunoglobulin G immunology, Immunotherapy, Adoptive, Leukemia, B-Cell therapy, Lymphoma, B-Cell therapy, Receptors, Chimeric Antigen, Vaccine-Preventable Diseases prevention & control
- Abstract
BACKGROUNDLittle is known about pathogen-specific humoral immunity after chimeric antigen receptor-modified T (CAR-T) cell therapy for B cell malignancies.METHODSWe conducted a prospective cross-sectional study of CD19-targeted or B cell maturation antigen-targeted (BCMA-targeted) CAR-T cell therapy recipients at least 6 months posttreatment and in remission. We measured pathogen-specific IgG against 12 vaccine-preventable infections and the number of viral and bacterial epitopes to which IgG was detected ("epitope hits") using a serological profiling assay. The primary outcome was the proportion of participants with IgG levels above a threshold correlated with seroprotection for vaccine-preventable infections.RESULTSWe enrolled 65 children and adults a median of 20 months after CD19- (n = 54) or BCMA- (n = 11) CAR-T cell therapy. Among 30 adults without IgG replacement therapy (IGRT) in the prior 16 weeks, 27 (90%) had hypogammaglobulinemia. These individuals had seroprotection to a median of 67% (IQR, 59%-73%) of tested infections. Proportions of participants with seroprotection per pathogen were comparable to population-based studies, but most individuals lacked seroprotection to specific pathogens. Compared with CD19-CAR-T cell recipients, BCMA-CAR-T cell recipients were half as likely to have seroprotection (prevalence ratio, 0.47; 95% CI, 0.18-1.25) and had fewer pathogen-specific epitope hits (mean difference, -90 epitope hits; 95% CI, -157 to -22).CONCLUSIONSeroprotection for vaccine-preventable infections in adult CD19-CAR-T cell recipients was comparable to the general population. BCMA-CAR-T cell recipients had fewer pathogen-specific antibodies. Deficits in both groups support the need for vaccine and immunoglobulin replacement therapy studies.FUNDINGSwiss National Science Foundation (Early Postdoc Mobility grant P2BSP3_188162), NIH/National Cancer Institute (NIH/NCI) (U01CA247548 and P01CA018029), NIH/NCI Cancer Center Support Grants (P30CA0087-48 and P30CA015704-44), American Society for Transplantation and Cellular Therapy, and Juno Therapeutics/BMS.
- Published
- 2021
- Full Text
- View/download PDF
175. Circulating tumour DNA in B-cell lymphomas: current state and future prospects.
- Author
-
Lakhotia R and Roschewski M
- Subjects
- Biomarkers, Tumor genetics, Circulating Tumor DNA genetics, Disease Progression, Humans, Lymphoma, B-Cell genetics, Lymphoma, B-Cell therapy, Monitoring, Physiologic, Biomarkers, Tumor blood, Circulating Tumor DNA blood, Lymphoma, B-Cell blood
- Abstract
Circulating tumour DNA (ctDNA) is a highly versatile analyte and an emerging biomarker for detection of tumour-specific sequences in lymphoid malignancies. Since ctDNA is derived from tumour cells throughout the body, it overcomes fundamental limitations of tissue biopsies by capturing the complete molecular profile of tumours, including those from inaccessible anatomic locations. Assays for ctDNA are minimally invasive and serial sampling monitors the effectiveness of therapy and identifies minimal residual disease below the detection limit of standard imaging scans. Dynamic changes in ctDNA levels measure real-time tumour kinetics, and early reductions in ctDNA during treatment correlate with clinical outcomes in multiple B-cell lymphomas. After therapy, ctDNA can effectively discriminate between patients who achieved a complete molecular remission from those with residual treatment-resistant disease. Serial monitoring of ctDNA after therapy can detect early molecular relapse and identify drug-resistant clones that harbour targetable mutations. In order for ctDNA to reach its full potential, the standardization and harmonization of the optimal pre-analytical and analytical techniques for B-cell lymphomas is a critically necessary requirement. Prospective validation of ctDNA within clinical studies is also required to determine its clinical utility as an adjunctive decision-making tool., (© 2021 British Society for Haematology and John Wiley & Sons Ltd.)
- Published
- 2021
- Full Text
- View/download PDF
176. C-reactive protein and ferritin levels and length of intensive care unit stay in patients with B-cell lymphomas treated with axicabtagene ciloleucel.
- Author
-
Melody M, Rahman ZA, Saunders H, Diaz PL, Gannon N, Rosenthal A, Ayala E, Tun HW, Murthy H, Roy V, Foran J, Castro JE, Guru P, and Kharfan-Dabaja MA
- Subjects
- Adult, Aged, Biological Products, Female, Hospitalization, Humans, Immunotherapy, Adoptive, Intensive Care Units, Lymphoma, B-Cell blood, Lymphoma, B-Cell diagnosis, Male, Middle Aged, Prognosis, Retrospective Studies, Young Adult, Antigens, CD19 therapeutic use, C-Reactive Protein analysis, Ferritins blood, Lymphoma, B-Cell therapy
- Abstract
Objective/background: Chimeric antigen receptor (CAR) T-cell is an effective therapy in relapsed/refractory large B-cell lymphomas that, due to its unique toxicities, often requires escalation of care to the intensive care unit (ICU) setting. C-reactive protein (CRP) and ferritin are serum inflammatory markers associated with onset and persistence of CAR T-cell-related toxicity., Methods: We retrospectively analyzed 34 patients treated with axicabtagene ciloleucel (axi-cel) who were divided into two groups: patients requiring admission to the ICU during initial hospitalization (n = 13, 38%) and those who did not (n = 21, 62%). Primary objective was to examine possible relationships between serum ferritin and/or CRP levels with the need for, and length of, ICU stay between these groups., Results: All 13 patients admitted to the ICU developed cytokine release syndrome (CRS) and 11 of them also developed neurotoxicity (NT). Of the 21 patients in the non-ICU group, 18 developed CRS and 5 patients developed NT. Grade of CRS and NT were higher in ICU versus non-ICU patients (p = .03 and .001, respectively). There was no correlation between CRP levels at time of ICU admission and length of ICU stay (correlation of 0.41, p = .17). Yet, there was an association between serum ferritin levels and length of ICU stay (R
2 = 0.73) which did not reach statistical significance (correlation of 0.21, p = .49)., Conclusion: Notwithstanding the limitations of the small sample size, our study suggests that an elevated ferritin level at the time of escalation of medical care may be possibly indicative of anticipated prolonged ICU hospitalization in patients treated with axi-cel. A large multicenter study is certainly needed to confirm this observation., Competing Interests: Declaration of Competing Interest M.A.K-D declares consultancy for Daiichi Sankyo and Pharmacyclics. All other authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2020 King Faisal Specialist Hospital & Research Centre. Published by Elsevier Ltd. All rights reserved.)- Published
- 2021
- Full Text
- View/download PDF
177. The evolving role of allogeneic haematopoietic cell transplantation in the era of chimaeric antigen receptor T-cell therapy.
- Author
-
Dholaria B, Savani BN, Huang XJ, Nagler A, Perales MA, and Mohty M
- Subjects
- Adult, Allografts, Child, Child, Preschool, Humans, Hematopoietic Stem Cell Transplantation, Immunotherapy, Adoptive, Lymphoma, B-Cell therapy, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma therapy
- Abstract
Chimaeric antigen receptor T-cell (CAR T) therapy has revolutionized the management of many haematological malignancies. It is associated with impressive disease responses in relapsed or refractory high-grade B-cell non-Hodgkin lymphoma (B-NHL) and acute lymphoblastic leukaemia (B-ALL) with durable remissions in a subset of patients. Historically, haematopoietic cell transplantation (HCT) has been the standard consolidation strategy for many of these patients who are now being treated with CAR T. Relapses are frequent after CD19 CAR T therapy in B-ALL and consolidation with allogeneic HCT (allo-HCT) may improve survival of patients with high-risk disease. There appears to be a clear difference in B-ALL outcomes between paediatric and adult patients, with the latter having a much higher risk of relapse after CAR T therapy. Late relapses are infrequent in patients with B-NHL and consolidation with allo-HCT may not be needed in patients who achieve a complete remission after CAR T therapy. Future registry-based and prospective studies will hopefully provide the needed data in the future to risk-stratify the recipients of CAR T therapy. Meanwhile, we provide guidance on patient selection and practical issues with performing allo-HCT after CAR T therapy., (© 2021 British Society for Haematology and John Wiley & Sons Ltd.)
- Published
- 2021
- Full Text
- View/download PDF
178. A Primer on Chimeric Antigen Receptor T-cell Therapy: What Does It Mean for Pathologists?
- Author
-
Cushman-Vokoun AM, Voelkerding KV, Fung MK, Nowak JA, Thorson JA, Duncan HL, Kalicanin T, Anderson MW, and Yohe S
- Subjects
- Education, Medical, Continuing methods, Humans, Lymphoma, B-Cell immunology, Pathologists education, Precursor Cell Lymphoblastic Leukemia-Lymphoma immunology, T-Lymphocytes metabolism, United States, United States Food and Drug Administration, Immunotherapy, Adoptive methods, Lymphoma, B-Cell therapy, Precursor Cell Lymphoblastic Leukemia-Lymphoma therapy, Receptors, Antigen, T-Cell immunology, Receptors, Chimeric Antigen immunology, T-Lymphocytes immunology
- Abstract
Context.—: Chimeric antigen receptor T-cell (CAR-T) technology has shown great promise in both clinical and preclinical models in mediating potent and specific antitumor activity. With the advent of US Food and Drug Administration-approved CAR-T therapies for B-cell lymphoblastic leukemia and B-cell non-Hodgkin lymphomas, CAR-T therapy is poised to become part of mainstream clinical practice., Objective.—: To educate pathologists on CAR-T and chimeric antigen receptor-derived cellular therapy, provide a better understanding of their role in this process, explain important regulatory aspects of CAR-T therapy, and advocate for pathologist involvement in the delivery and monitoring of chimeric antigen receptor-based treatments. Much of the focus of this article addresses US Food and Drug Administration-approved therapies; however, more general issues and future perspectives are considered for therapies in development., Design.—: A CAR-T workgroup, facilitated by the College of American Pathologists Personalized Health Care Committee and consisting of pathologists of various backgrounds, was convened to develop a summary guidance paper for the College of American Pathologists Council on Scientific Affairs., Results.—: The workgroup identified gaps in pathologists' knowledge of CAR-T therapy, including uncertainty in the role of the clinical laboratory in supporting CAR-T therapy. The workgroup considered these issues and summarized the findings to assist pathologists to become stakeholders in CAR-T therapy administration., Conclusions.—: This manuscript serves to both educate pathologists on CAR-T therapy and serve as a point of initial discussions in areas of CAR-T science, clinical therapy, and regulatory issues as CAR-T therapies continue to be introduced into clinical practice.
- Published
- 2021
- Full Text
- View/download PDF
179. [CAR T-cell therapy for malignant B-cell lymphoma : A new treatment paradigm].
- Author
-
Balke-Want H and Borchmann P
- Subjects
- Child, Humans, Immunotherapy, Adoptive, T-Lymphocytes, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell therapy, Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Abstract
Following the first demonstration of efficacy of anti-CD19-directed chimeric antigen receptor (CAR) T cells in a patient with relapsed chronic lymphocytic leukemia (CLL) in 2011, pivotal studies for this innovative therapy were initially conducted in multiple relapsed or refractory (r/r) childhood and young adult acute B‑cell leukemia and in aggressive adult B‑cell lymphoma. The studies demonstrated efficacy even in chemotherapy-refractory disease, resulting in the first approval of autologous and genetically engineered T cells for the treatment of r/r B‑cell acute lymphoblastic leukemia (B-ALL) in the US for the product tisagenlecleucel (Kymriah®, Novartis) back in 2018. Approval for the treatment of r/r aggressive B‑cell lymphoma followed shortly thereafter for tisagenlecleucel and axicabtagene ciloleucel (Yescarta, Kite/Gilead). This review focuses on the treatment of aggressive B‑cell lymphoma and other CD19 positive B‑cell lymphomas by summarizing the study results of clinically tested CAR T cells, discussing possible resistance mechanisms, and providing an outlook on ongoing studies with new target antigens for the treatment of B‑cell lymphomas.
- Published
- 2021
- Full Text
- View/download PDF
180. Dual Effects of Cyclooxygenase Inhibitors in Combination With CD19.CAR-T Cell Immunotherapy.
- Author
-
Yang M, Wang L, Ni M, Neuber B, Wang S, Gong W, Sauer T, Schubert ML, Hückelhoven-Krauss A, Xia R, Ge J, Kleist C, Eckstein V, Sellner L, Müller-Tidow C, Dreger P, Schmitt M, and Schmitt A
- Subjects
- Antigens, CD19 immunology, Apoptosis drug effects, Cell Proliferation drug effects, Coculture Techniques, Cyclooxygenase 2 Inhibitors pharmacology, Cytokines metabolism, Cytotoxicity, Immunologic drug effects, Humans, Inflammation Mediators metabolism, K562 Cells, Lymphocyte Activation drug effects, Lymphoma, B-Cell immunology, Lymphoma, B-Cell metabolism, Lymphoma, B-Cell pathology, Receptors, Chimeric Antigen metabolism, T-Lymphocytes immunology, T-Lymphocytes metabolism, T-Lymphocytes transplantation, Antigens, CD19 genetics, Aspirin pharmacology, Celecoxib pharmacology, Cyclooxygenase Inhibitors pharmacology, Immunotherapy, Adoptive, Lymphoma, B-Cell therapy, Receptors, Chimeric Antigen genetics, T-Lymphocytes drug effects
- Abstract
Chimeric antigen receptor T (CAR-T) cells targeting CD19 came into clinical practice for the treatment of B cell lymphoma in 2018. However, patients being treated for B cell lymphoma often suffer from comorbidities such as chronic pain, cardiovascular diseases and arthritis. Thus, these patients frequently receive concomitant medications that include nonsteroidal anti-inflammatory drugs (NSAIDs) like cyclooxygenase (COX) inhibitors. Celecoxib, a selective COX-2 inhibitor, and aspirin, a non-selective COX-1 and COX-2 inhibitor, are being used as anti-inflammatory, analgesic and anti-pyretic drugs. In addition, several studies have also focused on the anti-neoplastic properties of COX-inhibitors. As the influence of COX-inhibitors on CD19.CAR-T cells is still unknown, we investigated the effect of celecoxib and aspirin on the quantity and quality of CD19.CAR-T cells at different concentrations with special regard to cytotoxicity, activation, cytokine release, proliferation and exhaustion. A significant effect on CAR-T cells could be observed for 0.1 mmol/L of celecoxib and for 4 mmol/L of aspirin. At these concentrations, we found that both COX-inhibitors could induce intrinsic apoptosis of CD19.CAR-T cells showing a significant reduction in the ratio of JC-10 red to JC-10 green CAR-T cells from 6.46 ± 7.03 (mean ± SD) to 1.76 ± 0.67 by celecoxib and to 4.41 ± 0.32 by aspirin, respectively. Additionally, the ratios of JC-10 red to JC-10 green Daudi cells were also decreased from 3.41 ± 0.30 to 0.77 ± 0.06 by celecoxib and to 1.26 ± 0.04 by aspirin, respectively. Although the cytokine release by CD19.CAR-T cells upon activation was not hampered by both COX-inhibitors, activation and proliferation of CAR-T cells were significantly inhibited via diminishing the NF-ĸB signaling pathway by a significant down-regulation of expression of CD27 on CD4
+ and CD8+ CAR-T cells, followed by a clear decrease of phosphorylated NF-ĸB p65 in both CD4+ and CD8+ CAR-T cells by a factor of 1.8. Of note, COX-inhibitors hampered expansion and induced exhaustion of CAR-T cells in an antigen stress assay. Collectively, our findings indicate that the use of COX-inhibitors is a double-edged sword that not only induces apoptosis in tumor cells but also impairs the quantity and quality of CAR-T cells. Therefore, COX-inhibitors should be used with caution in patients with B cell lymphoma under CAR-T cell therapy., Competing Interests: MS received funding for collaborative research from Apogenix, Hexal and Novartis, travel grants from Hexal and Kite, he received financial support for educational activities and conferences from bluebird bio, Kite and Novartis, he is a board member for MSD and (co-)PI of clinical trials of MSD, GSK, Kite and BMS, as well as co-founder and shareholder of TolerogenixX Ltd. AS received travel grants from Hexal and Jazz Pharmaceuticals, research grant from Therakos/Mallinckrodt and is co-founder of TolerogenixX Ltd. AS and LW are part- or full-time employers of TolerogenixX Ltd. LS was employed by Takeda Pharma Vertrieb GmbH & Co. KG. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2021 Yang, Wang, Ni, Neuber, Wang, Gong, Sauer, Schubert, Hückelhoven-Krauss, Xia, Ge, Kleist, Eckstein, Sellner, Müller-Tidow, Dreger, Schmitt and Schmitt.)- Published
- 2021
- Full Text
- View/download PDF
181. Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma.
- Author
-
Jain MD, Zhao H, Wang X, Atkins R, Menges M, Reid K, Spitler K, Faramand R, Bachmeier C, Dean EA, Cao B, Chavez JC, Shah B, Lazaryan A, Nishihori T, Hussaini M, Gonzalez RJ, Mullinax JE, Rodriguez PC, Conejo-Garcia JR, Anasetti C, Davila ML, and Locke FL
- Subjects
- Adult, Aged, Cytokines blood, Female, Ferritins blood, Humans, Lymphoma, B-Cell genetics, Lymphoma, B-Cell immunology, Male, Middle Aged, RNA, Neoplasm biosynthesis, Receptors, Chimeric Antigen, Treatment Failure, Tumor Burden, Young Adult, Biological Products immunology, Immunotherapy, Adoptive, Interferons physiology, Lymphoma, B-Cell therapy, Myeloid-Derived Suppressor Cells immunology, Tumor Escape
- Abstract
Axicabtagene ciloleucel (axi-cel) is a chimeric antigen receptor (CAR) T-cell therapy for relapsed or refractory large B-cell lymphoma (LBCL). This study evaluated whether immune dysregulation, present before CAR T-cell therapy, was associated with treatment failure. Tumor expression of interferon (IFN) signaling, high blood levels of monocytic myeloid-derived suppressor cells (M-MDSCs), and high blood interleukin-6 and ferritin levels were each associated with a lack of durable response. Similar to other cancers, we found that in LBCL tumors, IFN signaling is associated with the expression of multiple checkpoint ligands, including programmed cell death-ligand 1, and these were higher in patients who lacked durable responses to CAR-T therapy. Moreover, tumor IFN signaling and blood M-MDSCs associated with decreased axi-cel expansion. Finally, patients with high tumor burden had higher immune dysregulation with increased serum inflammatory markers and tumor IFN signaling. These data support that immune dysregulation in LBCL promotes axi-cel resistance via multiple mechanistic programs: insufficient axi-cel expansion associated with both circulating M-MDSC and tumor IFN signaling, which also gives rise to expression of immune checkpoint ligands., (© 2021 by The American Society of Hematology.)
- Published
- 2021
- Full Text
- View/download PDF
182. B Cell Lymphomas of the GI Tract.
- Author
-
Small S, Barnea Slonim L, Williams C, and Karmali R
- Subjects
- Humans, Lymphoma, Follicular diagnosis, Lymphoma, Follicular genetics, Lymphoma, Follicular physiopathology, Lymphoma, Follicular therapy, Lymphoproliferative Disorders diagnosis, Lymphoproliferative Disorders etiology, Lymphoproliferative Disorders physiopathology, Lymphoproliferative Disorders therapy, Gastrointestinal Neoplasms genetics, Gastrointestinal Neoplasms physiopathology, Gastrointestinal Neoplasms therapy, Lymphoma, B-Cell diagnosis, Lymphoma, B-Cell genetics, Lymphoma, B-Cell physiopathology, Lymphoma, B-Cell therapy
- Abstract
Purpose of the Review: Primary GI lymphomas of B cell origin are a diverse group of lymphomas. In this article, we provide an overview of the diagnosis, pathologic and molecular features, and management of these varied lymphomas., Recent Findings: The most common primary GI lymphomas are diffuse large B cell lymphoma (DLBCL) and marginal zone lymphomas (MZL), but follicular lymphomas (FL), mantle cell lymphomas (MCL), post-transplant lymphoproliferative disorders (PTLD), and Burkitt lymphoma of the GI tract also occur. Many features of these lymphomas are similar to their nodal counterparts, but certain clinical and biological aspects are unique. Diagnostic and treatment strategies for these lymphomas continue to evolve over time. There are ongoing discoveries about the unique pathophysiology, molecular characteristics, and complications of primary B cell GI lymphomas that are already leading to improvements in management of this histologically diverse set of lymphomas.
- Published
- 2021
- Full Text
- View/download PDF
183. The value of complete remission according to positron emission tomography prior to autologous stem cell transplantation in lymphoma: a population-based study showing improved outcome.
- Author
-
Noring K, Carlsten M, Sonnevi K, and Wahlin BE
- Subjects
- Adolescent, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Female, Hematopoietic Stem Cell Transplantation mortality, Hodgkin Disease diagnostic imaging, Hodgkin Disease mortality, Hodgkin Disease therapy, Humans, Lymphoma mortality, Lymphoma, B-Cell diagnostic imaging, Lymphoma, B-Cell mortality, Lymphoma, B-Cell therapy, Lymphoma, Mantle-Cell diagnostic imaging, Lymphoma, Mantle-Cell mortality, Lymphoma, Mantle-Cell therapy, Lymphoma, T-Cell diagnostic imaging, Lymphoma, T-Cell mortality, Lymphoma, T-Cell therapy, Lymphoma, T-Cell, Peripheral diagnostic imaging, Lymphoma, T-Cell, Peripheral mortality, Lymphoma, T-Cell, Peripheral therapy, Male, Middle Aged, Progression-Free Survival, Recurrence, Remission Induction, Retrospective Studies, Transplantation Conditioning methods, Transplantation, Autologous, Treatment Outcome, Young Adult, Hematopoietic Stem Cell Transplantation statistics & numerical data, Lymphoma diagnostic imaging, Lymphoma therapy, Positron Emission Tomography Computed Tomography statistics & numerical data
- Abstract
Background: Chimeric antigen-receptor T-cell and bispecific antibody therapies will likely necessitate a reconsideration of the role of autologous stem-cell transplantation (ASCT) in lymphoma. Patients who are likely to profit from ASCT need to be better identified., Methods: Here, we investigated the value of positron emission tomography/computerized tomography (PET/CT) before ASCT. All 521 patients transplanted for lymphoma 1994-2019 at Karolinska (497 conditioned with BEAM) were included., Results: Outcome improved over three calendar periods 1994-2004, 2005-2014, 2015-2019 (2-year overall survival [OS]: 66, 73, 83%; P = 0.018). Non-relapse mortality (NRM) at 100 days over the three periods were 9.8, 3.9, 2.9%, respectively. The OS improvement between 1994 and 2004 and 2005-2014 was due to lower NRM (P = 0.027), but the large OS advance from 2015 was not accompanied by a significant reduction in NRM (P = 0.6). The fraction of PET/CT as pre-ASCT assessment also increased over time: 1994-2004, 2%; 2005-2014, 24%; 2015-2019, 60% (P < 0.00005). Complete responses (PET/CT-CR) were observed in 77% and metabolically active partial responses (PET/CT-PR) in 23%. PET/CT-CR was a predictor for survival in the entire population (P = 0.0003), also in the subpopulations of aggressive B-cell (P = 0.004) and peripheral T-cell (P = 0.024) lymphomas. Two-year OS and progression-free survival (OS/PFS) for patients in PET/CT-CR were in relapsed/refractory aggressive B-cell lymphoma 87%/75% and peripheral T-cell lymphoma 91%/78%. The corresponding figures in PET/CT-PR were 43%/44 and 33%/33%. Patients with solitary PET/CT-positive lesions showed acceptable outcome with ASCT followed by local irradiation (2-year OS/PFS 80%/60%). CT was less discriminative: 2-year OS/PFS: CT-CR, 76%/66%; CT-PR, 62%/51%. Outcome was inferior after BEAC compared with BEAM conditioning., Conclusions: We conclude that the improved outcome reflects better, PET/CT-informed, identification of patients who should proceed to ASCT. The excellent survival of patients in PET/CT-CR indicates that ASCT should remain part of standard therapy for lymphoma.
- Published
- 2021
- Full Text
- View/download PDF
184. Targeted alpha immunotherapy of CD20-positive B-cell lymphoma model: dosimetry estimate of 225 Ac-DOTA-rituximab using 64 Cu-DOTA-rituximab.
- Author
-
Lee CH, Lim I, Woo SK, Kim W, Kim KI, Lee KC, Song K, and Lim SM
- Subjects
- Animals, Mice, Humans, Cell Line, Tumor, Immunotherapy, Mice, Inbred BALB C, Tissue Distribution, Organometallic Compounds chemistry, Heterocyclic Compounds, 1-Ring chemistry, Rituximab chemistry, Antigens, CD20 immunology, Antigens, CD20 metabolism, Copper Radioisotopes chemistry, Lymphoma, B-Cell diagnostic imaging, Lymphoma, B-Cell therapy, Monte Carlo Method, Radiometry, Positron Emission Tomography Computed Tomography
- Abstract
Objective: The aim of this study was to evaluate the radiation dosimetry of alpha-emitter
225 Ac-DOTA-rituximab using Monte Carlo simulation of64 Cu-DOTA-rituximab., Methods: CD20 expression was evaluated in lymphoma cell lines (Jurkat and Raji). DOTA-rituximab was conjugated and then chelated by64 Cu. Tumor xenograft models were established in BALB/c-nu mice. Animal PET/CT imaging was obtained after tail vein injection with and without a pre-dose of 2 mg of cold rituximab. Specific binding of tumors was evaluated by an organ distribution assay and autoradiography. CD20 expression in tumor tissues was evaluated by immunohistochemistry. The residence time was calculated using64 Cu-DOTA-rituximab PET/CT acquisition data using OLINDA/EXM software.225 Ac-DOTA-rituximab tumor dosimetry was performed using Monte Carlo simulation with64 Cu-DOTA-rituximab PET/CT images., Results: Specific binding of Raji cells (CD20 positive) was 90 times that of Jurkat cells (CD20 negative) (p < 0.0001). Immunoreactivity was more than 75%. PET/CT imaging with64 Cu-DOTA-rituximab was specifically observed in tumors. The radioactivity of the tumor was much higher than that of other organs, and tumor uptake was related to CD20 expression. The predicted human dose for the administration of64 Cu-DOTA-rituximab was measured as the effective dose (1.07E-02 mSv/MBq). In the tumor region, equivalent doses of225 Ac-DOTA-rituximab (14 SvRBE5 /MBq) were much higher (74-fold) than those of64 Cu-DOTA-rituximab (0.19 SvRBE5 /MBq) (p < 0.01)., Conclusion: Tumor dosimetry of225 Ac-DOTA-rituximab can be estimated via the Monte Carlo simulation of64 Cu-DOTA-rituximab.225 Ac-DOTA-rituximab can be employed for lymphoma as targeted alpha therapy.- Published
- 2021
- Full Text
- View/download PDF
185. Immune imitation of tumor progression after anti-CD19 chimeric antigen receptor T cells treatment in aggressive B-cell lymphoma.
- Author
-
Danylesko I, Shouval R, Shem-Tov N, Yerushalmi R, Jacoby E, Besser MJ, Shimoni A, Davidson T, Beider K, Mevorach D, Fried S, Nagler A, and Avigdor A
- Subjects
- Adult, Antigens, CD19, Humans, Imitative Behavior, Immunotherapy, Adoptive, Positron Emission Tomography Computed Tomography, T-Lymphocytes, Lymphoma, B-Cell therapy, Receptors, Chimeric Antigen
- Abstract
We present three patients with aggressive non-Hodgkin's B-cell lymphoma (NHL) who received anti-CD19 chimeric antigen receptor T (CAR T) cells therapy after failure of several lines of chemotherapy that developed pseudo-progression. One-week clinical and radiological findings were consistent with tumor progression. Positron emission tomography-computed tomography (PET-CT) at 1 month post CAR T cells administration was consistent with treatment response. The rapid tumor growth and subsequent resolution are suggestive of tumor pseudo-progression mediated secondary to infiltration and immune activation of CAR T cells. Overall, 56 adult patients with NHL were enrolled in a phase 1b/2 in house clinical study with CD19 CAR T cells. Out of them 22/56 patients progressed as per PET-CT the 1 month post CAR T cells. In 14 patients, signs of progression started 7-10 days after CAR T cells infusion. In 11/14 patients, it was true progression, while in 3 it was pseudo-progression. Additional studies are warranted to describe the extent of this phenomenon and evaluate correlation with the CAR T activity and long-term disease control.
- Published
- 2021
- Full Text
- View/download PDF
186. Perspectives on outpatient administration of CAR-T cell therapy in aggressive B-cell lymphoma and acute lymphoblastic leukemia.
- Author
-
Myers GD, Verneris MR, Goy A, and Maziarz RT
- Subjects
- Cost-Benefit Analysis, Hospital Costs, Humans, Lymphoma, B-Cell economics, Lymphoma, B-Cell immunology, Lymphoma, B-Cell mortality, Patient Safety, Precursor Cell Lymphoblastic Leukemia-Lymphoma economics, Precursor Cell Lymphoblastic Leukemia-Lymphoma immunology, Precursor Cell Lymphoblastic Leukemia-Lymphoma mortality, Risk Assessment, Risk Factors, T-Lymphocytes immunology, Treatment Outcome, Ambulatory Care economics, Antigens, CD19 immunology, Immunotherapy, Adoptive adverse effects, Immunotherapy, Adoptive economics, Immunotherapy, Adoptive mortality, Lymphoma, B-Cell therapy, Precursor Cell Lymphoblastic Leukemia-Lymphoma therapy, Receptors, Chimeric Antigen genetics, T-Lymphocytes transplantation
- Abstract
Chimeric antigen receptor (CAR) T-cell therapies that specifically target the CD19 antigen have emerged as a highly effective treatment option in patients with refractory B-cell hematological malignancies. Safety and efficacy outcomes from the pivotal prospective clinical trials of axicabtagene ciloleucel, tisagenlecleucel and lisocabtagene maraleucel and the retrospective, postmarketing, real-world analyses have confirmed high response rates and durable remissions in patients who had failed multiple lines of therapy and had no meaningful treatment options. Although initially administered in the inpatient setting, there has been a growing interest in delivering CAR-T cell therapy in the outpatient setting; however, this has not been adopted as standard clinical practice for multiple reasons, including logistic and reimbursement issues. CAR-T cell therapy requires a multidisciplinary approach and coordination, particularly if given in an outpatient setting. The ability to monitor patients closely is necessary and proper protocols must be established to respond to clinical changes to ensure efficient, effective and rapid evaluation either in the clinic or emergency department for management decisions regarding fever, sepsis, cytokine release syndrome and neurological events, specifically immune effector cell-associated neurotoxicity syndrome. This review presents the authors' institutional experience with the preparation and delivery of outpatient CD19-directed CAR-T cell therapy., Competing Interests: Competing interests: GDM serves as a consultant on the study steering committee for Kymriah (tisagenlecleucel) and on the Speaker's Bureau for Kymriah (tisagenlecleucel). MRV reports salary and stock consultancy for Fate Therapeutics and reports salary from and serves on an advisory board for Novartis. AG has received consulting fees and his institution has received research funding from Acerta, Celgene, Constellation, Infinity, Infinity Verastem, Janssen, Karyopharm, Kite Pharma, Pharmacyclics, Genentech-Hoffman La Roche, AstraZeneca, Genentech and Hoffman La Roche. He is a consultant for Acerta, Celgene, Janssen, Kite Pharma, Pharmacyclics, Gilead, Medscape, MJH Associates, Physicians Education Resource and Xcenda. He has served on advisory boards for Janssen, Kite Pharma, Elsevier’s PracticeUpdate Oncology, and Gilead; has served as a moderator for OncLive Peer Exchange; and has served as an Advisor on Video for AstraZeneca. He is a member of steering committees for AstraZeneca and MorphoSys and Incyte. RTM is a member and chair of the Scientific Steering Committee for Tisagenlecleucel for DLBCL and receives honoraria and research funding from Novartis. He is a consultant for and receives honoraria from CRISPR Therapeutics, Incyte, and Juno Therapeutics; receives honoraria from Kite Therapeutics; and has patents and receives royalties from Athersys. RTM is employed by Oregon Health & Science University (OHSU) and has provided consultant services to and received payment from Novartis. This potential conflict of interest has been reviewed and managed by OHSU., (© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2021
- Full Text
- View/download PDF
187. Cutaneous lymphomas management during COVID-19 pandemic.
- Author
-
Vitiello P, Sica A, Ronchi A, Pastore F, Casale B, and Argenziano G
- Subjects
- Humans, COVID-19, Lymphoma, B-Cell therapy, Lymphoma, T-Cell, Cutaneous therapy, Skin Neoplasms therapy
- Published
- 2021
- Full Text
- View/download PDF
188. A cross-talk between CAR T cell subsets and the tumor microenvironment is essential for sustained cytotoxic activity.
- Author
-
Boulch M, Cazaux M, Loe-Mie Y, Thibaut R, Corre B, Lemaître F, Grandjean CL, Garcia Z, and Bousso P
- Subjects
- Animals, Antigens, CD19 immunology, Antigens, Neoplasm immunology, Cell Communication genetics, Cell Line, Tumor, Computational Biology methods, Cytokines metabolism, Disease Models, Animal, Gene Expression Profiling, Humans, Immunotherapy, Adoptive, Interferon-gamma biosynthesis, Lymphocyte Activation immunology, Lymphoma, B-Cell genetics, Lymphoma, B-Cell immunology, Lymphoma, B-Cell pathology, Lymphoma, B-Cell therapy, Mice, Neoplasms immunology, Neoplasms therapy, Receptors, Antigen, T-Cell genetics, Receptors, Chimeric Antigen genetics, Cell Communication immunology, Cytotoxicity Tests, Immunologic, Receptors, Antigen, T-Cell metabolism, Receptors, Chimeric Antigen metabolism, T-Lymphocyte Subsets immunology, T-Lymphocyte Subsets metabolism, Tumor Microenvironment immunology
- Abstract
Chimeric antigen receptor (CAR) T cell therapy relies on the activity of a large pool of tumor-targeting cytotoxic effectors. Whether CAR T cells act autonomously or require interactions with the tumor microenvironment (TME) remains incompletely understood. Here, we report an essential cross-talk between CAR T cell subsets and the TME for tumor control in an immunocompetent mouse B cell lymphoma model of anti-CD19 CAR T cell therapy. Using single-cell RNA sequencing, we revealed substantial modification of the TME during CAR T cell therapy. Interferon-γ (IFN-γ) produced by CAR T cells not only enhanced endogenous T and natural killer cell activity but was also essential for sustaining CAR T cell cytotoxicity, as revealed by intravital imaging. CAR T cell-derived IFN-γ facilitated host interleukin-12 production that supported host immune and CAR T cell responses. Compared with CD8
+ CAR T cells, CD4+ CAR T cells were more efficient at host immune activation but less capable of direct tumor killing. In summary, CAR T cells do not act independently in vivo but rely instead on cytokine-mediated cross-talk with the TME for optimal activity. Invigorating CAR T cell interplay with the host represents an attractive strategy to prevent relapses after therapy., (Copyright © 2021 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.)- Published
- 2021
- Full Text
- View/download PDF
189. Trispecific CD19-CD20-CD22-targeting duoCAR-T cells eliminate antigen-heterogeneous B cell tumors in preclinical models.
- Author
-
Schneider D, Xiong Y, Wu D, Hu P, Alabanza L, Steimle B, Mahmud H, Anthony-Gonda K, Krueger W, Zhu Z, Dimitrov DS, Orentas RJ, and Dropulić B
- Subjects
- Animals, Antigens, CD19, B-Lymphocytes, Humans, Mice, Receptors, Antigen, T-Cell, Sialic Acid Binding Ig-like Lectin 2, T-Lymphocytes, Immunotherapy, Adoptive, Lymphoma, B-Cell therapy
- Abstract
A substantial number of patients with leukemia and lymphoma treated with anti-CD19 or anti-CD22 monoCAR-T cell therapy relapse because of antigen loss or down-regulation. We hypothesized that B cell tumor antigen escape may be overcome by a chimeric antigen receptor (CAR) design that simultaneously targets three B cell leukemia antigens. We engineered trispecific duoCAR-T cells with lentiviral vectors encoding two CAR open reading frames that target CD19, CD20, and CD22. The duoCARs were composed of a CAR with a tandem CD19- and CD20-targeting binder, linked by the P2A self-cleaving peptide to a second CAR targeting CD22. Multiple combinations of intracellular T cell signaling motifs were evaluated. The most potent duoCAR architectures included those with ICOS, OX40, or CD27 signaling domains rather than those from CD28 or 4-1BB. We identified four optimal binder and signaling combinations that potently rejected xenografted leukemia and lymphoma tumors in vivo. Moreover, in mice bearing a mixture of B cell lymphoma lines composed of parental triple-positive cells, CD19-negative, CD20-negative, and CD22-negative variants, only the trispecific duoCAR-T cells rapidly and efficiently rejected the tumors. Each of the monoCAR-T cells failed to prevent tumor progression. Analysis of intracellular signaling profiles demonstrates that the distinct signaling of the intracellular domains used may contribute to these differential effects. Multispecific duoCAR-T cells are a promising strategy to prevent antigen loss-mediated relapse or the down-regulation of target antigen in patients with B cell malignancies., (Copyright © 2021 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.)
- Published
- 2021
- Full Text
- View/download PDF
190. The standardized uptake value calculated from 111 In-ibritumomab tiuxetan single-photon emission computed tomography/computed tomography is a useful predictor of the clinical response in patients treated by 90 Y- ibritumomab tiuxetan therapy.
- Author
-
Kume A, Toriihara A, Shimizu R, Harata N, Isogai J, and Tanaka H
- Subjects
- Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols adverse effects, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Biomarkers, Tumor, Biopsy, Disease Management, Female, Humans, Image Processing, Computer-Assisted, Lymphoma, B-Cell etiology, Lymphoma, B-Cell mortality, Male, Middle Aged, Neoplasm Staging, Prognosis, Progression-Free Survival, Retrospective Studies, Treatment Outcome, Antibodies, Monoclonal administration & dosage, Indium Radioisotopes, Lymphoma, B-Cell diagnosis, Lymphoma, B-Cell therapy, Single Photon Emission Computed Tomography Computed Tomography methods
- Abstract
90 Y-Ibritumomab tiuxetan (IT) therapy is a radioimmunotherapy for indolent B-cell lymphoma. Several predictors of insufficient therapeutic effects have been reported. We performed a retrospective study at a single institute to investigate whether111 In SPECT/CT can predict the therapeutic effects and grade of cytopenia due to90 Y-IT therapy. We enrolled 16 consecutive patients who underwent90 Y-IT therapy, including 15 who underwent111 In-IT SPECT/CT. After90 Y-IT therapy, there were 4 patients in complete remission in whom the lesion SUVmax 111 In-IT SPECT/CT and soluble IL-2 receptor were significantly lower than those of the other patients (P<0.05 and P<0.05, respectively). Based on the log-rank test of factors associated with the progression-free survival (PFS), ≥2 previous treatment regimens was significantly associated with a poor prognosis (P<0.05). The SUV on111 In-IT SPECT/CT may be a good predictor of the clinical response to90 Y-IT therapy.- Published
- 2021
- Full Text
- View/download PDF
191. DA-EPOCH-R therapy for high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements in a patient with renal dysfunction.
- Author
-
Mitobe M, Kawamoto K, Suzuki T, Suwabe T, Shibasaki Y, Masuko M, Inoue K, Miyoshi H, Ohshima K, Sone H, and Takizawa J
- Subjects
- Antineoplastic Combined Chemotherapy Protocols adverse effects, Biomarkers, Biomarkers, Tumor, Biopsy, Cyclophosphamide adverse effects, Cyclophosphamide therapeutic use, Doxorubicin adverse effects, Doxorubicin therapeutic use, Etoposide adverse effects, Etoposide therapeutic use, Female, Humans, Immunohistochemistry, In Situ Hybridization, Fluorescence, Kidney Diseases diagnosis, Kidney Function Tests, Lymphoma, B-Cell complications, Lymphoma, B-Cell diagnosis, Male, Neoplasm Grading, Neoplasm Staging, Prednisone adverse effects, Prednisone therapeutic use, Proto-Oncogene Proteins c-bcl-2, Proto-Oncogene Proteins c-bcl-6, Proto-Oncogene Proteins c-myc genetics, Rituximab administration & dosage, Tomography, X-Ray Computed, Treatment Outcome, Vincristine adverse effects, Vincristine therapeutic use, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Gene Rearrangement, Kidney Diseases complications, Lymphoma, B-Cell genetics, Lymphoma, B-Cell therapy
- Abstract
High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements, also known as double-hit lymphoma, has been reported as refractory to R-CHOP therapy and requires more intensive regimens. However, intensive and safe regimens for patients with renal dysfunction are unknown. Herein, we report the successful use of DA-EPOCH-R therapy for double-hit lymphoma in a 64-year-old man with renal dysfunction. The patient had lymphoma-induced bilateral ureteral obstruction. Although renal dysfunction remained after removing the obstruction using R-CHOP therapy, we completed six cycles of DA-EPOCH-R therapy without any major adverse events. DA-EPOCH-R therapy may be a safe regimen for renal dysfunction patients.
- Published
- 2021
- Full Text
- View/download PDF
192. Anti-CD19 CAR T cells potently redirected to kill solid tumor cells.
- Author
-
Ambrose C, Su L, Wu L, Dufort FJ, Sanford T, Birt A, Hackel BJ, Hombach A, Abken H, Lobb RR, and Rennert PD
- Subjects
- Animals, Antigens, CD19 immunology, B-Lymphocytes immunology, B-Lymphocytes pathology, Cell Line, Tumor, Cell Proliferation, Coculture Techniques, Cytotoxicity, Immunologic, ErbB Receptors genetics, ErbB Receptors immunology, Gene Expression, Genetic Vectors immunology, Genetic Vectors metabolism, Humans, Lentivirus genetics, Lentivirus immunology, Lymphocyte Activation, Lymphoma, B-Cell genetics, Lymphoma, B-Cell immunology, Lymphoma, B-Cell pathology, Mice, Mice, SCID, Protein Binding, Receptor, ErbB-2 immunology, Receptors, Chimeric Antigen immunology, T-Lymphocytes cytology, Treatment Outcome, Xenograft Model Antitumor Assays, Antigens, CD19 genetics, Immunotherapy, Adoptive methods, Lymphoma, B-Cell therapy, Receptor, ErbB-2 genetics, Receptors, Chimeric Antigen genetics, T-Lymphocytes immunology
- Abstract
Successful CAR T cell therapy for the treatment of solid tumors requires exemplary CAR T cell expansion, persistence and fitness, and the ability to target tumor antigens safely. Here we address this constellation of critical attributes for successful cellular therapy by using integrated technologies that simplify development and derisk clinical translation. We have developed a CAR-CD19 T cell that secretes a CD19-anti-Her2 bridging protein. This cell therapy strategy exploits the ability of CD19-targeting CAR T cells to interact with CD19 on normal B cells to drive expansion, persistence and fitness. The secreted bridging protein potently binds to Her2-positive tumor cells, mediating CAR-CD19 T cell cytotoxicity in vitro and in vivo. Because of its short half-life, the secreted bridging protein will selectively accumulate at the site of highest antigen expression, ie. at the tumor. Bridging proteins that bind to multiple different tumor antigens have been created. Therefore, antigen-bridging CAR-CD19 T cells incorporate critical attributes for successful solid tumor cell therapy. This platform can be exploited to attack tumor antigens on any cancer., Competing Interests: The authors have read the journal’s policy, and the authors of the study have the following competing interests to declare: Aleta Biotherapeutics is wholly funded by Advent Life Science Partners, a venture capital firm. Advent Life Sciences provided support in the form of salaries for authors [CA, LS, LW, FJD, AB, PDR], and paid consulting fees [RRL]. Aleta Biotherapeutics funded BJH’s research at the University of Minnesota for a period of time, resulting in a shared patent filing. The agreement with Univ Minnesota was for a one-time payment from Aleta to secure all of the patent rights (assigned by Dr Hackel to UMN). The patent is "CD19 VARIANTS" US Appln. No. 62/599,211; Filed: December 15, 2017. The research sponsorship has since ended and that financial relationship in no manner has influenced the work contained in this manuscript. Aleta Biotherapeutics paid consultancy fees to HA in the past. The consultancy has since ended and that financial relationship in no manner has influenced the work contained in this manuscript. This does not alter our adherence to PLOS ONE policies on sharing data and materials. There are no other products in development or marketed products associated with this research to declare.
- Published
- 2021
- Full Text
- View/download PDF
193. 4SCAR2.0: a multi-CAR-T therapy regimen for the treatment of relapsed/refractory B cell lymphomas.
- Author
-
Jiao C, Zvonkov E, Lai X, Zhang R, Liu Y, Qin Y, Savchenko V, Gabeeva N, Chung TH, Sheng L, and Chang LJ
- Subjects
- Adult, Female, Humans, Immunotherapy, Adoptive adverse effects, Male, Middle Aged, Treatment Outcome, Immunotherapy, Adoptive methods, Lymphoma, B-Cell therapy, Neoplasm Recurrence, Local therapy, Receptors, Chimeric Antigen therapeutic use
- Published
- 2021
- Full Text
- View/download PDF
194. Oncolytic virotherapy-mediated anti-tumor response: a single-cell perspective.
- Author
-
Ramelyte E, Tastanova A, Balázs Z, Ignatova D, Turko P, Menzel U, Guenova E, Beisel C, Krauthammer M, Levesque MP, and Dummer R
- Subjects
- Adult, Aged, Aged, 80 and over, Biological Products immunology, Dendritic Cells immunology, Female, Herpesvirus 1, Human immunology, Humans, Killer Cells, Natural immunology, Lymphoma, B-Cell virology, Male, Middle Aged, Monocytes immunology, Oncolytic Virotherapy methods, Single-Cell Analysis, T-Lymphocytes, Cytotoxic immunology, T-Lymphocytes, Regulatory immunology, Lymphoma, B-Cell immunology, Lymphoma, B-Cell therapy, Oncolytic Viruses immunology
- Abstract
Talimogene laherparepvec (T-VEC) is a genetically modified herpes simplex 1 virus (HSV-1) approved for cancer therapy. We investigate its effect on the clinical, histological, single-cell transcriptomic, and immune repertoire level using repeated fine-needle aspirates (FNAs) of injected and noninjected lesions in primary cutaneous B cell lymphoma (pCBCL). Thirteen patients received intralesional T-VEC, 11 of which demonstrate tumor response in the injected lesions. Using single-cell sequencing of the FNAs, we identify the malignant population and separate three pCBCL subtypes. Twenty-four hours after the injection, we detect HSV-1
T-VEC transcripts in malignant and nonmalignant cells of the injected lesion but not of the noninjected lesion. Oncolytic virotherapy results in a rapid eradication of malignant cells. It also leads to interferon pathway activation and early influx of natural killer cells, monocytes, and dendritic cells. These events are followed by enrichment in cytotoxic T cells and a decrease of regulatory T cells in injected and noninjected lesions., Competing Interests: Declaration of interests The project was sponsored by University of Zurich, Switzerland, partially supported by a research grant provided by Amgen. R.D. has intermittent, project focused consulting and/or advisory relationships with Novartis, Merck Sharp & Dhome, Bristol-Myers Squibb (BMS), Roche, Amgen, Takeda, Pierre Fabre, Sun Pharma, Sanofi, Catalym, Second Genome, Regeneron, and Alligator outside the submitted work. Research in C.B.’s lab was supported by the Swiss National Science Foundation, ETH domain Personalized Health and Related Technologies (PHRT-510). E.G. was supported by the Promedica Stiftung (1406/M and 1412/M), the Swiss Cancer Research Foundation (KFS-4243-08-2017), and the Clinical Research Priority Program of the University of Zurich outside the submitted work. E.R. has intermittent, project focused consulting relationships with Amgen, BMS, and Sanofi outside the submitted work. Other authors have no interests to declare., (Copyright © 2020 Elsevier Inc. All rights reserved.)- Published
- 2021
- Full Text
- View/download PDF
195. Peripheral eosinophil counts predict efficacy of anti-CD19 CAR-T cell therapy against B-lineage non-Hodgkin lymphoma.
- Author
-
Jia Q, Qin D, He F, Xie Q, Ying Z, Zhang Y, Song Y, Cheng JN, Zuo X, Xu L, Fang H, Hu C, Peng L, Jin T, Shi Z, Alexander PB, Wang Y, Liu Y, Han W, Zhu J, Wang P, Li QJ, and Zhu B
- Subjects
- Adult, Aged, Animals, Antigens, CD19, Cell Line, Tumor, Disease Models, Animal, Female, Humans, Leukocyte Count, Lymphoma, B-Cell blood, Male, Mice, Middle Aged, Prognosis, Progression-Free Survival, Young Adult, Eosinophils, Immunotherapy, Adoptive, Lymphoma, B-Cell therapy, Receptors, Chimeric Antigen
- Abstract
Rationale: The onset of cytokine release syndrome (CRS) and in vivo persistence of anti-CD19 chimeric antigen receptor T (CAR-T) cells after infusion correlate with clinical responsiveness. However, there are no known baseline biomarkers that can predict the prognosis of patients with B-lineage non-Hodgkin lymphoma (B-NHL). The aim of this study was to identify blood cell populations associated with beneficial outcomes in B-NHL patients administered CAR-T cell immunotherapies. Methods: We enumerated peripheral blood and CAR-T cells by retrospectively analyzing three CAR-T cell trials involving 65 B-NHL patients. We used a preclinical model to elucidate the eosinophil mechanism in CAR-T cell therapy. Results: During an observation period up to 30 mo, B-NHL patients with higher baseline eosinophil counts had higher objective response rates than those with low eosinophil counts. Higher baseline eosinophil counts were also significantly associated with durable progression-free survival (PFS). The predictive significance of baseline eosinophil counts was validated in two independent cohorts. A preclinical model showed that eosinophil depletion impairs the intratumoral infiltration of transferred CAR-T cells and reduces CAR-T cell antitumor efficacy. Conclusion: The results of this study suggest that peripheral eosinophils could serve as stratification biomarkers and a recruitment machinery to facilitate anti-CD19 CAR-T cell therapy in B-NHL patients., Competing Interests: Competing Interests: The authors declare the following financial interests/personal relationships that may be considered potential competing interests: Q-J.L. and P.W. are scientific cofounders of HRAIN Biotechnology Co., Ltd., Shanghai, and hold shares in this company., (© The author(s).)
- Published
- 2021
- Full Text
- View/download PDF
196. Targeted In Vivo Delivery of NF-κB Decoy Inhibitor Augments Sensitivity of B Cell Lymphoma to Therapy.
- Author
-
Zhang Z, Zhao X, Wang D, Moreira D, Su YL, Alcantara M, Swiderski P, Wong J, Hui S, Forman S, Kwak L, and Kortylewski M
- Subjects
- Animals, Apoptosis, Cell Proliferation, Humans, Lymphoma, B-Cell genetics, Lymphoma, B-Cell immunology, Lymphoma, B-Cell pathology, Mice, Mice, Inbred BALB C, Mice, Inbred NOD, Mice, SCID, Oligodeoxyribonucleotides genetics, Tumor Cells, Cultured, Xenograft Model Antitumor Assays, Lymphoma, B-Cell therapy, NF-kappa B antagonists & inhibitors, Oligodeoxyribonucleotides administration & dosage, Oligodeoxyribonucleotides antagonists & inhibitors, Radiation Tolerance drug effects, Toll-Like Receptor 9 antagonists & inhibitors
- Abstract
Despite recent advances, non-Hodgkin's B cell lymphoma patients often relapse or remain refractory to therapy. Therapeutic resistance is often associated with survival signaling via nuclear factor κB (NF-κB) transcription factor, an attractive but undruggable molecular target. In this study, we describe a bipartite inhibitor comprising a NF-κB-specific decoy DNA tethered to a CpG oligodeoxynucleotide (ODN) targeting Toll-like receptor-9-expressing B cell lymphoma cells. The Bc-NFκBdODN showed efficient uptake by human diffuse large B cell (U2932, OCI-Ly3), Burkitt (RaJi), and mantle cell (Jeko1) lymphomas, respectively. We confirmed that Bc-NFκBdODN inhibited NF-κB nuclear translocation and DNA binding, resulting in CCND2 and MYC downregulation. Bc-NFκBdODN enhanced radiosensitivity of lymphoma cells in vitro. In xenotransplanted human lymphoma, local injections of Bc-NFκBdODN reduced NF-κB activity in whole tumors. When combined with a local 3-Gy dose of radiation, Bc-NFκBdODN effectively arrested OCI-Ly3 lymphoma progression. In immunocompetent mice, intratumoral injections of Bc-NFκBdODN suppressed growth of directly treated and distant A20 lymphomas, as a result of systemic CD8 T cell-dependent immune responses. Finally, systemic administration of Bc-NFκBdODN to mice bearing disseminated A20 lymphoma induced complete regression and extended survival of most of the treated mice. Our results underscore clinical relevance of this strategy as monotherapy and in support of radiation therapy to benefit patients with resistant or relapsed B cell lymphoma., Competing Interests: Declaration of Interests M.K. and P.S. are on the patent application submitted by CoH that covers the design of oligonucleotides presented in this report. The remaining authors declare no competing interests., (Copyright © 2020 The American Society of Gene and Cell Therapy. Published by Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
197. Predicting Outcomes following Anti-CD19 CAR T Cell Therapy in Aggressive B Cell Lymphomas.
- Author
-
Ho C and Svoboda J
- Subjects
- Antigens, CD19, Humans, Immunotherapy, Adoptive, Lymphoma, B-Cell therapy
- Published
- 2021
- Full Text
- View/download PDF
198. Efficacy and safety of chimeric antigen receptor T cell immunotherapy in B-cell non-Hodgkin lymphoma: a systematic review and meta-analysis.
- Author
-
Wang N, Meng Y, Wu Y, He J, and Liu F
- Subjects
- Adult, Aged, Aged, 80 and over, Antigens, CD19 immunology, Antigens, CD20 immunology, Clinical Trials as Topic, Cytokine Release Syndrome chemically induced, Female, Humans, Lymphoma, B-Cell immunology, Male, Middle Aged, Neurotoxicity Syndromes etiology, Receptors, Antigen, T-Cell immunology, T-Lymphocytes transplantation, Treatment Outcome, Young Adult, Immunotherapy, Adoptive adverse effects, Lymphoma, B-Cell therapy, Receptors, Chimeric Antigen immunology, T-Lymphocytes immunology
- Abstract
Aim: The aim was to evaluate the efficacy and safety of chimeric antigen receptor T (CAR-T) cell in B-cell non-Hodgkin lymphoma (B-NHL). Materials & methods: A meta-analysis was conducted using eligible clinical trials, which were obtained from electronic medical literature databases. Results: A total of 24 clinical trials with 590 patients were included. The best overall response rate was 66% and complete remission rate was 46%. The incidence rates of cytokine-release syndrome and neurotoxicity (grade ≥ 3) were 9 and 5%, respectively. The various clinical factors were analyzed. Autogenic CAR-T cell may lead to improved efficacy than allogeneic CAR-T cell. CD20 CAR-T cell may show increased efficacy than CD19 CAR-T cell. Conclusion: CAR-T immunotherapy has remarkable efficacy and low toxicity in relapsed/refractory B-NHL.
- Published
- 2021
- Full Text
- View/download PDF
199. Pluripotent stem cell-derived CD19-CAR iT cells effectively eradicate B-cell lymphoma in vivo.
- Author
-
Lv C, Chen S, Hu F, Huang D, Wang T, Du J, Wang J, and Wu H
- Subjects
- Animals, Core Binding Factor Alpha 2 Subunit metabolism, Hematopoietic Stem Cells cytology, Hematopoietic Stem Cells metabolism, Homeodomain Proteins metabolism, Lymphoma, B-Cell immunology, Lymphoma, B-Cell metabolism, Mice, Mice, Inbred C57BL, Antigens, CD19 immunology, Immunotherapy, Adoptive methods, Lymphoma, B-Cell therapy, Pluripotent Stem Cells cytology
- Published
- 2021
- Full Text
- View/download PDF
200. CAR T-Cell Therapy in Hematologic Malignancies: Clinical Role, Toxicity, and Unanswered Questions.
- Author
-
Gill S and Brudno JN
- Subjects
- Antigens, CD19, Humans, Receptors, Antigen, T-Cell, Immunotherapy, Adoptive, Leukemia, Lymphocytic, Chronic, B-Cell therapy, Lymphoma, B-Cell therapy
- Abstract
At the time of writing, five anti-CD19 CAR T-cell products are approved by the U.S. Food and Drug Administration for seven different indications in lymphoid malignancies, including B-cell non-Hodgkin lymphoma, pediatric B-cell acute lymphoblastic leukemia, and multiple myeloma. CAR T cells for chronic lymphocytic leukemia, acute myeloid leukemia, and less common malignancies such as T-cell lymphomas and Hodgkin lymphoma are being tested in early-phase clinical trials worldwide. The purpose of this overview is to describe the current landscape of CAR T cells in hematologic malignancies, outline their outcomes and toxicities, and explain the outstanding questions that remain to be addressed.
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.